SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X Quarterly Report pursuant to Section 13 or 15 (d) of the Securities
Exchange Act of 1934 for the quarterly period ended March 31, 1999.
Or
_ Transition Report pursuant to Section 13 or 15 (d) of the Securities
Exchange Act of 1934 for the
transition period from ______ to ______.
Commission file number 0-20619
Matria Healthcare, Inc.
(Exact name of registrant as specified in its charter)
Delaware 58-2205984
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
1850 Parkway Place, 12th Floor, Marietta, Georgia 30067
(Address of principal executive offices) (Zip Code)
(770) 767-4500
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
YES X NO
--------- -------
The number of shares outstanding of the issuer's only class of Common Stock,
$.01 par value, together with associated Common Stock purchase rights, as of
April 30, 1999 was 36,537,921.
<PAGE>
Part I - Financial Information
Item 1. Financial Statements
Matria Healthcare, Inc. and Subsidiaries
Consolidated Condensed Balance Sheets
(Dollars in thousands, except per share amounts)
(Unaudited)
<TABLE>
<CAPTION>
March 31, December 31,
ASSETS 1999 1998
---------------- --------------
<S> <C> <C>
Current assets:
Cash and cash equivalents ................................................ $ 7,246 9,109
Short-term investments ................................................... -- 2,859
Trade accounts receivable, less allowances of $23,721 and $21,235 at March
31, 1999 and December 31,
1998, respectively .................................................... 46,735 37,311
Inventories .............................................................. 8,377 1,699
Prepaid expenses and other current assets ................................ 2,716 4,556
---------- --------
Total current assets .................................................. 65,074 55,534
Property and equipment, less accumulated depreciation of
$31,786 and $30,238 at March 31, 1999 and
December 31, 1998, respectively .......................................... 19,113 16,865
Intangible assets, less accumulated amortization of $3,300
and $612 at March 31, 1999 and December 31, 1998,
respectively ............................................................. 141,791 16,261
Deferred tax asset ........................................................... 20,000 --
Cash surrender value of life insurance ....................................... 6,674 4,425
Other assets ................................................................. 2,820 3,949
---------- --------
$255,472 97,034
---------- --------
</TABLE>
See accompanying notes to consolidated condensed financial statements.
<PAGE>
Matria Healthcare, Inc. and Subsidiaries
Consolidated Condensed Balance Sheets
(Dollars in thousands except, per share amounts)
(Unaudited)
<TABLE>
<CAPTION>
March 31, December 31,
LIABILITIES AND SHAREHOLDERS' EQUITY: 1999 1998
----------------- ----------------
<S> <C> <C>
Current liabilities:
Current installments of long-term debt
and obligations under capital leases $13,822 718
Accounts payable, principally trade 23,863 8,939
Accrued liabilities 17,769 9,536
------------ ---------
Total current liabilities 55,454 19,193
Long-term debt and obligations under capital leases,
excluding current installments 95,177 18,385
Other long-term liabilities 9,002 9,575
------------ ---------
Total liabilities 159,633 47,153
Preferred stock, $.01 par value. Authorized 50,000,000 shares:
Series A convertible, redeemable; issued 10,000 shares at
March 31, 1999; none at December 31, 1998;
redemption value $10,000 10,000 --
Series B redeemable; issued 35,000 shares at
March 31, 1999; none at December 31, 1998;
redemption value $35,000 30,672 --
Common shareholders' equity:
Common stock, $.01 par value. Authorized 100,000,000 shares;
issued and outstanding 36,468,834 and 36,409,544 shares
at March 31, 1999 and December 31, 1998, respectively 365 364
Additional paid-in capital 285,026 280,585
Accumulated other comprehensive loss (178) --
Accumulated deficit (226,511) (227,533)
Notes receivable and accrued interest from shareholder (3,535) (3,535)
------------ ---------
Total shareholders' equity 55,167 49,881
------------ ---------
$ 255,472 97,034
------------ ---------
</TABLE>
See accompanying notes to consolidated condensed financial statements.
<PAGE>
Matria Healthcare, Inc. and Subsidiaries
Consolidated Condensed Statements of Operations
(Dollars and shares in thousands, except per share amounts)
(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended
March 31,
1999 1998
<S> <C> <C>
Revenues $ 59,359 32,818
Cost of revenues 31,276 13,325
Selling and administrative expenses 20,561 14,708
Provision for doubtful accounts 1,906 1,490
Amortization of intangible assets 2,599 9,147
------------ ---------
Operating earnings (loss) 3,017 (5,852)
Interest income (expense), net (1,503) 18
Other income, net 157 186
------------ ---------
Earnings (loss) before income taxes 1,671 (5,648)
Income taxes - -
------------ ---------
Net earnings (loss) 1,671 (5,648)
Accretion of Series B redeemable preferred stock (87) -
Preferred stock dividend requirements (649) -
------------ ---------
Net earnings (loss) available to common shareholders $ 935 (5,648)
------------ ---------
Net earnings (loss) per common share:
Basic $ 0.03 (0.15)
------------ ---------
Diluted $ 0.03 (0.15)
------------ ---------
Weighted average shares outstanding:
Basic 36,439 36,826
------------ ---------
Diluted 36,939 36,826
------------ ---------
</TABLE>
See accompanying notes to consolidated condensed financial statements.
<PAGE>
Matria Healthcare, Inc. and Subsidiaries
Consolidated Condensed Statements of Cash Flows
(Amounts in thousands)
(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended March 31,
1999 1998
<S> <C> <C>
Cash Flows from Operating Activities:
Net earnings (loss) .................................................... $ 1,671 (5,648)
Adjustments to reconcile net earnings (loss) to net cash
provided by (used in) operating activities:
Depreciation and amortization .................................. 4,403 10,395
Provision for doubtful accounts ................................ 1,906 1,490
Changes in assets and liabilities, net of effect of acquistions:
Accounts receivable ....................................... (3,003) (3,224)
Inventories, prepaids and other current assets ............ 2,949 (917)
Intangible and other noncurrent assets .................... (2,451) (484)
Accounts payable and accrued liabilities .................. (3,932) (5,260)
Accrued pension cost ...................................... 180 (3,217)
Other current liabilities ................................. 717 (2,573)
--------- ---------
Net cash provided by (used in) operating activities .... 2,440 (9,438)
--------- ---------
Cash Flows from Investing Activities:
Purchases of property and equipment .................................... (1,860) (679)
Sales of short-term investments ........................................ 2,859 7,821
Purchases of short-term investments .................................... -- (1,500)
Acquisition of businesses, net of cash acquired (93,019) --
--------- ---------
Net cash provided by (used in) investing activities ............ (92,020) 5,642
--------- ---------
Cash Flows from Financing Activities:
Borrowings under credit agreement ...................................... 105,000 --
Proceeds from issuance of debt -- 334
Principal repayments of debt and capital lease obligations ............. (17,219) (359)
Proceeds from issuance of common stock ................................. 114 201
Other, net -- (60)
--------- ---------
Net cash provided by financing activities .............. 87,895 116
--------- ---------
Effect of exchange rate changes on cash and cash equivalents ............... (178) --
--------- ---------
Net decrease in cash and cash equivalents ............... (1,863) (3,680)
Cash and cash eqivalents at beginning of period ............................ 9,109 9,086
--------- ---------
Cash and cash equivalents at end of period $ 7,246 5,406
--------- ---------
</TABLE>
See accompanying notes to consolidated condensed financial statements.
<PAGE>
Notes to Consolidated Condensed
Financial Statements
(Amounts in thousands, except share and per share amounts)
(Unaudited)
1. General
The consolidated condensed financial statements as of March 31, 1999
and for the three months ended March 31, 1999 and 1998 are unaudited.
In the opinion of management, all adjustments, consisting of normal
recurring accruals, necessary for fair presentation of the consolidated
financial position and results of operations for the periods presented
have been included. Certain reclassifications of prior period
information have been made to conform to the current year presentation.
The results for the three-month period ended March 31, 1999 are not
necessarily indicative of the results for the full year ending December
31, 1999.
The consolidated condensed financial statements should be read in
conjunction with the consolidated financial statements and related
notes included in the Annual Report on Form 10-K of Matria Healthcare,
Inc. ("Matria" or the "Company") for the year ended December 31, 1998.
2. Net Earnings (Loss) Per Share of Common Stock
Basic earnings (loss) per common share available to common shareholders
are based on the weighted average number of common shares outstanding.
Diluted earnings (loss) per common share are based on the weighted
average number of common shares outstanding and dilutive potential
common shares, such as dilutive stock options and warrants, determined
using the treasury stock method.
3. Acquisitions
Effective January 1, 1999, the Company completed the acquisition of
substantially all of the assets of Gainor Medical Management, L.L.C.
("Gainor Medical"), for a purchase price of approximately $130,000. The
acquisition was accounted for under the purchase method of accounting
and resulted in purchased patient lists of $3,300, executive
non-compete agreements of $500 and goodwill of $113,653. The
acquisition agreement also provides for additional contingent purchase
price of up to $35,000 based on the 1999 financial performance of the
Gainor Medical businesses. The assets acquired included the outstanding
capital stock of and membership interests and other equity interests in
the subsidiaries of Gainor Medical. Results of its operations have been
included in the Company's consolidated results of operations effective
January 1, 1999. If earned, the contingent purchase price is payable by
the issuance of subordinated notes in the year 2000, and would be
recorded as additional goodwill when earned.
<PAGE>
At the closing of the transaction, the Company paid $83,758 of the
purchase price in cash to the seller, assumed approximately $1,242 in
debt and issued $45,000 in redeemable preferred stock and warrants of
the Company. The transaction also included a cash adjustment payable by
the Company of $6,573, one-half of which was paid at the closing and
the remaining one-half of which is payable during the second quarter of
1999.
As of the acquisition date of Gainor Medical, the Company had a net
operating loss carry forward of approximately $90,000. In connection
with this acquisition, the Company recognized a $20,000 deferred tax
asset and a corresponding decrease in goodwill for the estimated tax
benefits of the net operating loss carry forward to be realized in the
future as a result of the acquisition.
The cash portion of the purchase price was financed partially through a
$125,000 five-year bank credit facility, which the Company entered into
in January 1999 (See Note 4).
In January 1998, the Company converted a $250 note receivable from
Diabetes Management Services, Inc. ("DMS") and paid $500 cash to
acquire a 10% equity interest in DMS. During 1998, the Company made
advances to fund working capital of DMS totaling $1,335. In January
1999, the Company converted the notes receivable for these advances and
paid cash of $6,500 to acquire the remaining equity interests of DMS.
The acquisition was accounted for using the purchase method of
accounting and resulted in goodwill of $10,765. Results of DMS's
operations have been included in the Company's consolidated results of
operations effective January 1, 1999.
Summarized below are the unaudited pro forma results of operations of
the Company for the three months ended March 31, 1998 as if the
acquisitions described above and the Company's acquisition in July 1998
of Quality Diagnostic Services Inc. ("QDS") had been effective January
1, 1998. The results of operations of the 1998 and 1999 acquisitions
have been included in the consolidated condensed statements of
operations of the Company as of January 1, 1999 and therefore no pro
forma results are presented for the three months ended March 31, 1999.
Three Months Ended
March 31, 1998
<TABLE>
<CAPTION>
<S> <C>
Revenues $ 53,387
Net loss ( 8,437)
Net loss available to common shareholders (0.23)
</TABLE>
4. Long Term Debt
In January 1999, in connection with the acquisitions of Gainor Medical
and DMS, the Company replaced its prior credit facility with a $125,000
five-year bank credit facility. The new facility consists of an $80,000
term loan facility, payable $6,000 in
<PAGE>
1999, $12,000 in 2000, $14,000 in 2001, $16,000 in 2002, $20,000 in
2003 and $12,000 in 2004 and a $45,000 revolving credit facility. The
facility, which is collateralized by accounts receivable, inventories
and certain assets of the Company, provides, at the Company's option,
interest at the prime rate plus .375% to 1.75% or the LIBOR rate plus
1.5% to 2.5%. The facility requires a commitment fee payable quarterly,
in arrears, of .375% to .500%, based upon the unused portion. As of
March 31, 1999, the total outstanding amount under this facility was
$105,000 and the interest rate was 7.25%. Under this agreement, the
Company is required to maintain certain financial ratios. The agreement
places certain limitations on cash dividends. At March 31, 1999, the
Company was in compliance with these requirements.
5. Preferred Stock
In connection with the purchase of Gainor Medical, the Company
designated 16,500 shares and issued 10,000 shares of 4% Series A
convertible redeemable preferred stock ("Series A CRPS"), and
designated 60,000 shares and issued 35,000 shares of 8% Series B
redeemable preferred stock ("Series B RPS") with attached warrants to
purchase 4,000,000 shares of the Company's common stock at $3.00 per
share.
The Series A CRPS is convertible at any time into 2,222,222 shares of
common stock. At its option, the Company may redeem the Series A CRPS,
at any time beginning two years after the acquisition date, after the
30 day moving average of the closing price of the Company's stock has
exceeded $5.40 per share, at a redemption price of $1,222 per share.
The Series A CRPS has a mandatory redemption feature, which requires
the Company to redeem one third of the shares issued on each of the
eighth, ninth and tenth anniversary dates of the original issuance date
at the redemption price of $1,000 per share. Redemption may occur at
the holder's request, in the event there is a change of control of the
Company, as defined in the applicable shareholder agreement. Dividends
are payable quarterly, in arrears, in cash or additional shares of
Series A CRPS, or a combination thereof, at the option of the Company.
The Series A CRPS has been recorded at the mandatory redemption value.
At its option, the Company may redeem the Series B RPS in whole or in
part at any time at the redemption price of $1,000 per share. The
Series B RPS has a mandatory redemption feature which requires the
Company to redeem one third of the shares issued on each of the eighth,
ninth and tenth anniversary dates of the original issuance date, at the
redemption price of $1,000 per share. At issuance date, the Company
allocated $4,415 of the $35,000 total redemption value of Series B RPS
to the fair value of the warrants issued, using a Black-Scholes option
pricing model. This amount was recorded as a credit to additional
paid-in capital and is being accreted over the term of the Series B
RPS.
In the event of liquidation, holders of Series A CRPS and Series B RPS
are entitled to receive, from the assets available for distribution to
the shareholders, an amount in cash or property at fair market value,
equal to $1,000 per share plus unpaid dividends. The Company is
restricted from paying dividends on the Company's
<PAGE>
common stock until all unpaid dividends on the Series A CRPS and Series B RPS
are paid.
6. Business Segment Information
The Company's reportable business segments are the strategic business
units that offer different products and services. They are managed
separately, and the Company evaluates performance based on operating
earnings of the respective business unit.
As a result of the acquisitions in the last half of 1998 and the first
quarter of 1999, the Company's operations have been classified into three
reportable business segments, Women's Health, Diabetes Supplies and
Services and Cardiovascular. The Women's Health segment offers services
designed to assist physicians and payors in the cost effective management
of maternity patients including: specialized home nursing; risk
assessment; patient education and management; home uterine contraction
monitoring; infusion therapy; gestational diabetes management; and other
monitoring and clinical services as prescribed by the patient's
physician. The Diabetes Supplies and Services segment has two components:
diabetes disease management services and microsampling products which are
products used to obtain and test small samples of bodily fluids. The
Cardiovascular segment provides cardiac event monitoring, holter
monitoring and pacemaker follow-up services. The Other Segments include
three business segments that are below the quantitative threshold for
disclosure: respiratory disease management; infertility practice
management services; and clinical record software and services.
The accounting policies of the segments are the same as those for the
consolidated entity. There are no intersegment sales and operating
earnings (loss) by business segment excludes interest income, interest
expense, and corporate expenses.
<PAGE>
Summarized financial information as of and for the three-month periods
ended March 31, 1999 and 1998 by business segment follows:
<TABLE>
<CAPTION>
Revenues Operating earnings (loss)
1999 1998 1999 1998
<S> <C> <C> <C> <C>
Women's Health $26,620 29,363 2,761 (3,738)
Diabetes Supplies and Services 25,934 -- 1,437 --
Cardiovascular 3,690 -- 782 --
Other Segments 3,115 3,455 (936) (1,165)
------- ------- ------ ------
Total segments 59,359 32,818 4,044 (4,903)
General Corporate -- -- (1,027) (949)
Interest income (expense), net -- -- (1,503) 18
Other income (expenses), net -- -- 157 186
------- ------- ------ ------
Consolidated revenues and earnings
(loss) before income taxes $ 59,359 32,818 1,671 (5,648)
------- ------- ------ ------
</TABLE>
<TABLE>
<CAPTION>
Indentifiable
assets
March 31, December 31,
1999 1998
<S> <C> <C>
Women's Health $ 42,701 57,011
Diabetes Supplies and Services 148,502 39
Cardiovascular 15,774 14,383
Other Segment 4,823 6,543
General Corporate 43,672 19,058
------- -------
Consolidated Assets $255,472 97,034
------- -------
</TABLE>
The Company's revenues from outside the United States were less than 16%
of total revenues. No single customer accounted for 10% of consolidated
net revenue in either period.
7. Recent Accounting Pronouncements
In June 1998, the FASB issued Statement of Financial Accounting
Standards No. 133, "Accounting for Derivative Instruments and Hedging
Activities" ("SFAS No. 133"). SFAS No. 133, which is effective for
2000, requires all derivatives to be recorded on the balance sheet at
fair value and establishes accounting treatment for certain hedge
transactions. The Company is analyzing the implementation requirements
and currently does not anticipate there will be a material impact on
the results of operations or financial position after adoption of SFAS
No. 133.
8. Comprehensive Income
On January 1, 1998, the Company adopted Statement of Financial
Accounting
<PAGE>
Standards No. 130, "Reporting Comprehensive Income" ("SFAS No. 130").
SFAS No. 130 establishes standards for reporting and presentation of
comprehensive income and its components in a full set of financial
statements. For the Company, comprehensive income consists of net
earnings (loss) and foreign currency translation adjustments. The
statement requires only additional disclosures in the financial
statements, it does not affect the Company's financial position or
results of operations. Comprehensive income (loss) for the three months
ended March 31, 1999 and 1998 was $1,493 and ($5,648), respectively.
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations.
General
During 1998 and early 1999, the Company announced several strategic actions to
expand its business focus beyond managing the condition of pregnancy into other
disease management markets. These actions included: (i) the acquisition in July
1998 of Quality Diagnostic Services, Inc. ("QDS"), a cardiac event monitoring
company; (ii) the completion of a licensing agreement in October 1998 with
National Jewish Medical and Research Center ("National Jewish") to provide
services in the respiratory disease management market; and (iii) the acquisition
in January 1999 of the business and assets of Gainor Medical Management, L.L.C.
("Gainor Medical") and Diabetes Management Services, Inc. ("DMS"), diabetes
disease management companies. Disease management is an emerging healthcare
sector receiving a heightened focus in the healthcare industry, and the
competition in this sector is fragmented without a dominant leader. The
Company's management is confident that with the successful implementation of its
expansion strategies, the Company will become the dominant market leader in
disease management and that these strategies will result in significant revenue
growth in 1999 and beyond.
In connection with these acquisitions, the Company acquired intangible assets
that are being amortized over various useful lives from 5-15 years. The
amortization periods are based on, among other things, the nature of the
products and markets, the competitive position of the acquired companies and the
adaptability to changing market conditions of the acquired companies.
The following discussion of the results of operations and financial condition of
the Company should be read in conjunction with the consolidated financial
statements and related notes in the Company's Annual Report on Form 10-K for the
year ended December 31, 1998 and the Company's Report on Form 8-K/A filed on
April 5, 1999 as filed with the Securities and Exchange Commission. As a result
of the 1998 and 1999 strategic actions and acquisitions, the historical results
of operations are not indicative of the results that will be achieved by the
Company during future periods.
<PAGE>
Results of Operations
Revenues increased $26.541 million or 80.9% in the three-month period ended
March 31, 1999 as compared to the same period in 1998 primarily due to the
acquisitions of Gainor Medical and DMS, the businesses that are included in the
Diabetes Supplies and Services segment, and QDS, the business that is included
in the Cardiovascular segment. Revenues for the Diabetes Supplies and Services
and Cardiovascular segments were $25.934 million and $3.690 million,
respectively, in the first quarter of 1999. These increases were partly offset
by a 9.3% decline in revenues for the Company's Women's Health segment relating
to the decline in prescriptions for preterm labor management services and to a
decrease in revenues resulting from the termination of marketing rights of the
fetal fibronectin immunoassay test effective August 31, 1998.
Cost of revenues as a percentage of revenues increased to 52.7% for the
three-month period ended March 31, 1999 from 40.6% for the same period in 1998.
This increase resulted primarily from the acquisition of Gainor Medical where
cost of revenues is 70.0%. Approximately 48% of the revenues of Gainor Medical
are from the sales of microsampling products, which have a higher cost of
revenues than the service related businesses of the Company.
Selling and administrative expenses as a percentage of revenues decreased to
34.6% for the three-month period ended March 31, 1999 from 44.8% for the same
period in 1998 due to economies of scale achieved as a result of the Company's
acquisitions of Gainor Medical, QDS, and DMS.
The Company provides for estimated uncollectible accounts as revenues are
recognized. The provision for doubtful accounts as a percentage of revenues for
the Women's Health and Cardiovascular segments was 5.5% and 5.0% for the
three-month periods ended March 31, 1999 and 1998, respectively. The provision
for doubtful accounts as a percentage of revenues in the Diabetes Management
segment was approximately 1% in the first quarter of 1999. The provision is
adjusted periodically based upon the Company's quarterly evaluation of
historical collection experience, recoveries of amounts previously provided,
industry reimbursement trends and other relevant factors. Therefore, the
provision rate could vary on a quarterly basis.
Amortization of intangible assets decreased in the first quarter of 1999 as
compared to the same period in 1998 due to the writeoffs of intangible assets
taken in third and fourth quarters of 1998. The impact of the decrease resulting
from these writeoffs was offset by the additional amortization from the
intangible assets recorded as part of the acquisitions described above.
Interest expense increased in the first quarter of 1999 as compared to the same
period in 1998 due to a significant increase in borrowings related to business
acquisitions.
<PAGE>
The Company did not record a federal or state income tax provision in the
first quarter of 1999 or 1998 due to the Company's operating loss carry
forwards.
Liquidity and Capital Resources
As of March 31, 1999 the Company had cash and short-term investments of $7.246
million. Net cash provided by operations increased to $2.440 million for the
three-month period ended March 31, 1999, compared to cash used in operating
activities of $9.438 million for the same period of 1998. During 1998, cash flow
from operating activities was reduced by payments of $3.130 million relating to
severance costs of terminated employees, $2.587 million for performance
incentives paid under the Company's management incentive plan, and $1.328
million for lump-sum payouts related to the termination of a nonqualified
defined benefit pension plan.
The Company's accounts receivable days sales outstanding were 71 days as of
March 31, 1999 as compared to 96 days as of December 31, 1998. The reduction is
primarily due to lower days sales outstanding of the Gainor Medical businesses
accounts receivable. Only 30% of those businesses' sales are reimbursed by third
party and U.S. Government healthcare payors with the remaining sales being to
original equipment manufacturers, corporate employers and international
healthcare providers. As the sales to third party and U.S. Government healthcare
providers increase, the Company believes that the days sales outstanding will
increase.
The Asset Purchase Agreement for the acquisition of QDS provides for additional
cash payments of up to $6.000 million contingent upon 1999 revenues of the
Company's cardiac monitoring business.
The acquisition agreement for Gainor Medical provides for additional contingent
purchase price of up to $35.000 million based upon 1999 financial performance of
the Gainor Medical businesses. If earned, the Gainor Medical contingent purchase
price is payable by the issuance of subordinated notes to the seller in the
year 2000.
Capital expenditures of $1.860 million in the first quarter of 1999 relate
primarily to the purchases of patient equipment to support revenue growth in the
Cardiovascular segment and for the upgrade and expansion of computer information
systems in all segments of the Company. The Company expects to expend
approximately $10.500 million for capital items in 1999.
The Company believes that its current cash balances, expected cash flows from
operations and investing activities and amounts available under the existing
credit facility will be sufficient to finance its current operations.
<PAGE>
Year 2000 Issue
The Year 2000 issue refers generally to the data structure and
processing problem that may prevent systems from properly processing
date-sensitive information when the year changes to 2000. The Year 2000
issue affects information technology ("IT") systems, such as computer
programs and various types of electronic equipment that process date
information by using only two digits rather than four digits to define
the applicable year, and thus may recognize a date using "00" as the
year 1900 rather than the year 2000. The issue also affects some non-IT
systems, such as devices which rely on a microcontroller to process
date information. The Year 2000 issue could disrupt a company's
operations by generating erroneous data or causing system failures or
miscalulations.
The Company is involved in an extensive, ongoing program to identify
and correct problems arising from the Year 2000 issues. The program is
broken down into the following categories: (1) application systems; (2)
hardware; (3) monitoring equipment; and (4) computer applications of
its significant suppliers and significant payors.
The Company has evaluated the application systems in two parts: (1)
AS400 applications and (2) client server applications. The AS400
applications are believed to be capable of functioning properly beyond
the year 1999 at this time. Although the Company originally had
intended to replace its client server applications in 1999, because
that project will not be complete by year end 1999, the Company intends
to remediate the existing client server application systems in the
second quarter of 1999, a process that the Company estimates will take
four months to complete.
Remediation and testing of the AS400 hardware is 100% complete, and the
remediation and testing of the individual personal computers is
approximately 85% complete. The Company expects the remainder of
conversion and testing to be complete by July 1999.
In the first quarter of 1999, the Company completed its review of
embedded computer chips and software applications, which control
certain monitoring and other equipment. Remediation efforts are
expected to be minor and should be completed in the second quarter of
1999.
In 1998, the Company spent $60,000 for software and consulting fees
associated with the initial Year 2000 evaluation. Budgeted expenditures
in 1999 total $100,000. The Company is primarily addressing all Year
2000 issues with current staffing levels.
In the first quarter of 1999, the Company sent inquiries to its
significant suppliers and payors concerning the Year 2000 compliance of
their significant computer applications. The Company plans to send
second requests during the second quarter of 1999. The responses
received to date do not disclose any significant issues on
non-compliance. The Company will continue to evaluate Year 2000 risks
with respect to such suppliers and payors as responses are received. In
that connection, it should be noted that substantially all of the
Company's revenues are derived from
<PAGE>
reimbursement by third-party payors, and that the Company is dependent
upon such payors' evaluation of their Year 2000 compliance status to
assess such risks. If such payors are incorrect in their evaluation of
their own Year 2000 compliance status, this could result in delays or
errors in reimbursement to the Company, the effects of which could be
material to the Company.
In light of its compliance efforts and based on information currently
available, the Company believes that its risk associated with problems
arising from Year 2000 issues is not significant. However, because of
the many uncertainties associated with Year 2000 compliance issues, and
because the Company's assessment is necessarily based on information
from third-party payors and suppliers, there can be no assurance that
the Company's assessment is correct or as to the materiality or effect
of any failure of such assessment to be correct. The Company will
continue with its assessment process as described above and, to the
extent that changes in such assessment require it, will attempt to
develop alternatives or modifications to its compliance plan described
above. There can, however, be no assurance that such compliance plan,
as it may be changed, augmented or modified from time to time, will be
successful. There can be no assurance that the Year 2000 problem will
not have a material adverse effect on the Company's business, financial
condition and results of operations.
The SEC's recent guidance for Year 2000 disclosure calls for companies
to describe their most likely worst case Year 2000 scenarios.
Notwithstanding the aforementioned issues, the Company does not expect
significant problems at the turn of the century with internal
conversions and remediation. However, the most likely worst case
scenario is that if third-party payors are not able to reimburse the
Company after the turn of the century, the Company would be required to
sustain operations through existing cash balances or through the use of
available borrowings under its credit facilities. Also, the Company
would be required to add additional staff during the time period
leading up to and immediately following January 1, 2000, in order to
address any unexpected Year 2000 issues.
Forward-Looking Information
This Form 10-Q contains forward-looking statements and information that
are based on the Company's belief and assumptions, as well as
information currently available to the Company. From time to time, the
Company and its officers, directors or employees may make other oral or
written statements (including statements in press releases or other
announcements) that contain forward-looking statements and information.
Without limiting the generality of the foregoing, the words "believe,"
"anticipate," "estimate," "expect," "intend," "plan," "seek" and
similar expressions, when used in this report and in such other
statements, are intended to identify forward-looking statements. All
forward-looking statements and information in this Form 10-Q are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, and are intended to be covered by the
safe harbors created thereby. Such
<PAGE>
forward-looking statements are not guarantees of future performance and
are subject to risks, uncertainties and other factors that may cause
the actual results, performance or achievements of the Company to
differ materially from historical results or from any results expressed
or implied by such forward-looking statements. Such factors include,
without limitation, (i) changes in reimbursement rates, policies or
payment practices by third party payors, whether initiated by the payor
or legislatively maintained; (ii) the loss of major customers; (iii)
termination of the Company's exclusive supply agreement with Nissho
Corporation or failure to continue the agreement on terms currently in
effect; (iv) impairment of the Company's rights in intellectual
property; (v) increased or more effective competition; (vi) new
technologies that render obsolete or non-competitive products and
services offered by the Company; (vii) changes in regulations
applicable to the Company or failure to comply with existing
regulations; (viii) future health care or budget legislation or other
health reform initiatives; (ix) increased exposure to professional
negligence liability; (x) difficulties in successfully integrating
recently acquired businesses into the Company's operations and
uncertainties related to the future performance of such businesses;
(xi) losses due to foreign currency exchange rate fluctuations or
deterioration of economic conditions in foreign markets; (xii) costs
associated with Year 2000 related systems failures; (xiii) the amount
of sales to third parties and U.S. Government healthcare providers, and
(xiv) the risk factors discussed from time to time in the Company's SEC
reports, including but not limited to, its Annual Report on Form 10-K
for the year ended December 31, 1998. Many of such factors are beyond
the Company's ability to control or predict, and readers are cautioned
not to put undue reliance on such forward-looking statements. The
Company disclaims any obligation to update or review any
forward-looking statements contained in this report or in any statement
referencing the risk factors and other cautionary statements set forth
in this Report, whether as a result of new information, future events
or otherwise, except as may be required by the Company's disclosure
obligations in filings it makes with the SEC under Federal Securities
laws.
Item 3. Quantitative and Qualitative Disclosure About Market Risk
The Company is exposed to market risk from changes in interest rates
and foreign exchange rates.
The Company's primary interest rate risk relates to its variable rate
bank credit facility. At March 31, 1999, the Company's total variable
rate long-term debt obligation was $105.000 million. A hypothetical
100-basis point change in the interest rates would result in additional
interest expense of approximately $210,000 for the first quarter of
1999. There was no variable rate debt in the first quarter of 1998.
The Company does not believe it is exposed to significant foreign
exchange rate risk.
<PAGE>
PART II
OTHER INFORMATION
Item 2. Changes In Securities and Use of Proceeds.
On April 27,1999, the Company entered into an Amended and Restated
Rights Agreement with Sun Trust Bank, Atlanta with respect to the Company's
common stock (the "Amended Rights Agreement"), incorporating a second amendment
to the Rights Agreement dated January 30, 1996 (the "Rights Agreement"). The
substance of the second amendment was to change the requirement that the action
of a majority of the Continuing Directors (as defined in the Rights Agreement)
be required with respect to certain matters to require instead the action of a
majority of all Directors. In addition, the second amendment requires the
affirmative action of the Board of Directors for the issuance of rights
following a tender or exchange offer.
On January 19, 1999, in connection with the Gainor Medical acquisition,
the Company issued 10,000 shares of 4% Series A convertible redeemable preferred
stock ("Series A Preferred Stock") and 35,000 shares of 8% Series B redeemable
preferred stock ("Series B Preferred Stock") along with attached ten-year
warrants to purchase 4,000,000 shares of the Company's common stock at $3.00 per
share. The Series A and B Preferred stock and attached warrants were issued to
Gainor Medical as part of the purchase price for the acquisition of
substantially all of the assets and business of Gainor Medical. The issuance of
the preferred stock and warrants was exempt from registration under Section 4(2)
of the Securities Act as a transaction not involving a public offering. In
addition, Gainor Medical was sophisticated and had access to information about
the Company.
The shares of Series A Preferred Stock are convertible at any time into
a total of 2,222,222 shares of the Company's common stock at a rate of $4.50 per
share, while the ten-year warrants allow for the purchase of the Company's
common stock at $3.00 per share. For further discussion of the conversion and
exercise features of the preferred stock and warrants, see "Note 5 to
Consolidated Condensed Financial Statements."
Item 6. Exhibits and Reports on Form 8-K.
(a) Exhibits
4 Amended and Restated Rights Agreement, dated April 27, 1999 between
Matria and Sun Trust Bank, Atlanta.
11 Statement Regarding Computation of Earnings (Loss) Per Share
<PAGE>
(b) Reports on Form 8-K.
The Company filed a Current Report on Form 8-K on February 3, 1999,
which reported under Items 2 and 7 the consummation of the purchase of
Gainor Medical Management, LLC ("Gainor Medical") and amended same by
filing a Form 8-K/A on April 5, 1999 containing audited and pro forma
financial information on Gainor Medical.
27. Financial Data Schedule (for SEC purposes only)
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Matria Healthcare, Inc.
May 17, 1999 By: /s/ Donald R. Millard
Donald R. Millard
Director, President, Chief Executive
Officer and Chief Financial Officer
(Principal Financial Officer)
By: __/s/ Yvonne V. Scoggins
Yvonne V. Scoggins
Vice President, Chief Accounting Officer
and Treasurer
<PAGE>
Matria Healthcare, Inc. and Subsidiaries EXHIBIT 11
Computation of Earnings (Loss) per Share
(Amounts in thousands, except per share amounts)
(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended March 31,
1999 1998
<S> <C> <C>
Basic
Net earnings (loss) $ 1,671 (5,648)
Accretion on preferred stock (87) --
Preferred stock dividend requirements (649) --
------- -------
Net earnings (loss) available to common shareholders $ 935 (5,648)
------- -------
Shares:
Weighted average number of common shares outstanding 36,439 36,826
------- -------
Net earnings (loss) per common share $ 0.03 (0.15)
------- -------
Diluted
Net earnings (loss) available to common shareholders $ 935 (5,648)
------- -------
Shares:
Weighted average number of common shares outstanding 36,439 36,826
Shares issuable from assumed exercise of options and warrants 500) --
------- -------
36,939 36,826
------- -------
Net earnings (loss) per common share $ 0.03 (0.15)
------- -------
</TABLE>
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
quarterly report on Form 10-Q for the quarter ended March 31, 1999
</LEGEND>
<CIK> 0001007228
<NAME> N/A
<MULTIPLIER> 1000
<CURRENCY> US Dollars
<S> <C>
<PERIOD-TYPE> 3-mos
<FISCAL-YEAR-END> Dec-31-1999
<PERIOD-START> Jan-01-1999
<PERIOD-END> Mar-31-1999
<EXCHANGE-RATE> 1
<CASH> 7,246
<SECURITIES> 0
<RECEIVABLES> 70,456
<ALLOWANCES> (23,721)
<INVENTORY> 8,377
<CURRENT-ASSETS> 65,074
<PP&E> 50,899
<DEPRECIATION> (31,786)
<TOTAL-ASSETS> 255,472
<CURRENT-LIABILITIES> 55,454
<BONDS> 0
40,672
0
<COMMON> 365
<OTHER-SE> 54,802
<TOTAL-LIABILITY-AND-EQUITY> 255,472
<SALES> 0
<TOTAL-REVENUES> 59,359
<CGS> 0
<TOTAL-COSTS> 31,276
<OTHER-EXPENSES> 23,003
<LOSS-PROVISION> 1,906
<INTEREST-EXPENSE> 1,503
<INCOME-PRETAX> 1,671
<INCOME-TAX> 0
<INCOME-CONTINUING> 1,671
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 1,671
<EPS-PRIMARY> .03
<EPS-DILUTED> .03
</TABLE>
Exhibit 4
MATRIA HEALTHCARE, INC.
and
SunTrust Bank, Atlanta, Rights Agent
Amended and Restated Rights Agreement
Dated as of April 27, 1999
<PAGE>
TABLE OF CONTENTS
PAGE
Section 1. Certain Definitions................................................2
Section 2. Appointment of Rights Agent........................................7
Section 3. Issue of Rights Certificates.......................................8
Section 4. Form of Rights Certificates.......................................10
Section 5. Countersignature and Registration.................................11
Section 6 Transfer, Split Up, Combination and Exchange of Rights
Certificates; Mutilated, Destroyed, Lost or Stolen Rights
Certificates......................................................12
Section 7. Exercise of Rights; Purchase Price; Expiration Date of Rights.....13
Section 8. Cancellation and Destruction of Rights Certificates...............17
Section 9. Reservation and Availability of Capital Stock.....................17
Section 10. Common Stock Record Date.........................................20
Section 11. Adjustment of Purchase Price, Number and Kind of Shares or
Number of Rights.................................................20
Section 12. Certificate of Adjusted Purchase Price or Number of Shares.......36
Section 13. Consolidation, Merger or Sale or Transfer of Assets or
Earning Power....................................................37
Section 14. Fractional Rights and Fractional Shares..........................41
Section 15. All Rights of Action.............................................43
Section 16. Agreement of Rights Holders......................................43
Section 17. Rights Certificate Holder Not Deemed a Stockholder...............45
Section 18. Concerning the Rights Agent......................................45
Section 19. Merger or Consolidation or Change of Name of Rights Agent........46
Section 20. Duties of Rights Agent...........................................47
Section 21. Change of Rights Agent...........................................50
Section 22. Issuance of New Rights Certificates..............................51
Section 23. Redemption and Termination.......................................52
Section 24. Exchange.........................................................54
Section 25. Notice of Certain Events.........................................56
Section 26. Notices..........................................................58
Section 27. Supplements and Amendments.......................................58
Section 28. Successors.......................................................60
Section 29. Determinations and Actions by the Board of Directors, etc........60
Section 30. Benefits of this Agreement.......................................61
Section 31. Severability.....................................................61
Section 32. Governing Law....................................................61
Section 33. Counterparts.....................................................62
Section 34. Descriptive Headings.............................................62
Exhibit A [Form of Rights Certificate]......................................1
<PAGE>
AMENDED AND RESTATED RIGHTS AGREEMENT
AMENDED AND RESTATED RIGHTS AGREEMENT, dated as of April 27, 1999 between
MATRIA HEALTHCARE, INC., a Delaware corporation (the "Company"), and SunTrust
Bank, Atlanta, a Georgia banking corporation (the "Rights Agent").
W I T N E S S E T H
WHEREAS, on January 30, 1996, the Board of Directors of the Company
approved and adopted the Rights Agreement between the Company and the Rights
Agent (the "Original Agreement") and authorized the issuance pursuant to the
Original Agreement of one Right for each share of common stock, par value $0.01
per share, of the Company (the "Common Stock") issued pursuant to the Agreement
and Plan of Merger dated as of October 2, 1995, as amended as of December 4,
1995, by and among the Company, Healthdyne, Inc. and Tokos Medical Corporation
(Delaware) (the "Merger Agreement"), and has authorized the issuance of one
Right (as such number may hereinafter be adjusted pursuant to the provisions of
Section 11(p) hereof) for each share of Common Stock of the Company issued
between the Effective Time (as defined in the Merger Agreement) (whether
originally issued or delivered from the Company's treasury) and the Distribution
Date, each Right initially representing the right to purchase one one-hundredth
of a share of Common Stock of the Company, upon the terms and subject to the
conditions hereinafter set forth (the "Rights"); and
WHEREAS, on December 21, 1998 and April 27, 1999, the Board of
Directors of the Company adopted amendments to the Original Agreement (as so
amended, the "Agreement"); and
<PAGE>
WHEREAS, on April 27, 1999, the Board of Directors of the Company
authorized and directed that the Agreement be restated to reflect all amendments
approved to date;
NOW, THEREFORE, in consideration of the premises and the mutual
agreements herein set forth, the parties hereby agree as follows:
Section 1. Certain Definitions. For purposes of this Agreement, the
following terms have the meanings indicated:
(a) "Acquiring Person" shall mean any Person who or which, together with
all Affiliates and Associates of such Person, shall be the Beneficial Owner of
15% or more of the shares of Common Stock then
outstanding, but shall not include the Company, any Subsidiary of the Company,
any employee benefit plan of the Company or of any Subsidiary of the Company, or
any Person or entity organized, appointed or established by the Company for or
pursuant to the terms of any such plan. Notwithstanding the foregoing, no Person
shall be deemed to be an "Acquiring Person" either (i) as a result of the
acquisition of Common Stock by the Company which, by reducing the number of
shares of Common Stock outstanding, increases the proportional number of shares
beneficially owned by such Person together with all Affiliates and Associates of
such Person; except that if (A) a Person would become an Acquiring Person (but
for the operation of this subclause (i)) as a result of the acquisition of
Common Stock by the Company, and (B) after such share acquisition by the
Company, such Person or an Affiliate or Associate of such Person, becomes the
Beneficial Owner of any additional Common Stock, then such Person shall be
deemed an Acquiring Person unless, upon becoming the Beneficial Owner of such
additional shares of Common Stock, such Person is the Beneficial Owner of less
than 15% of the then outstanding shares of Common Stock, or (ii) if (A) within 8
days after such Person would otherwise have become an Acquiring Person (but for
the operation of this subclause (ii)), such Person notifies the Board of
Directors that such Person did so inadvertently and (B) within 2 days after such
notification, such Person is the Beneficial Owner of less than 5% of the
outstanding shares of Common Stock. Provided further, however, that neither any
Investor (as defined in that certain Standstill Agreement dated as of January
19, 1999, between the Company, Mark J. Gainor and SZ Investments, L.L.C. (the
"Standstill Agreement")) nor any such Investor's Permitted Transferees (as
defined in the Standstill Agreement) shall be deemed to be an Acquiring Person
solely by virtue of (x) the execution of the Purchase and Sale Agreement dated
as of December 21, 1998 (the "Purchase Agreement") between the Company and
Gainor Medical Management, L.L.C., a Georgia limited liability company ("GMM"),
<PAGE>
(y) the execution of the Standstill Agreement, or (z) the consummation of any of
the transactions contemplated and expressly permitted by the Purchase Agreement
or Section 3.2(a), (b), or (c) of the Standstill Agreement, except that if any
Investor (or any Permitted Transferee) acquires Matria Voting Securities (as
defined in the Standstill Agreement) other than in an acquisition expressly
permitted by Section 3.2(a), (b) or (c) of the Standstill Agreement, such Matria
Voting Securities, together with all other Matria Voting Securities then
Beneficially Owned by such Investor (or such Investor's Permitted Transferees),
shall be counted in determining whether such Investor (or any Permitted
Transferee) is an Acquiring Person.
(b) "Affiliate" and "Associate" shall have the respective meanings
ascribed to such terms in Rule 12b-2 of the General Rules and Regulations under
the Securities Exchange Act of 1934, as amended and in effect on the date of
this Agreement (the "Exchange Act").
(c) A Person shall be deemed the "Beneficial Owner" of, and shall
be deemed to "beneficially own," any securities:
(i) which such Person or any of such Person's Affiliates or Associates,
directly or indirectly, has the right to acquire (whether such right is
exercisable immediately or only after the passage of time) pursuant to any
agreement, arrangement or
understanding (whether or not in writing) or upon the exercise of
conversion rights, exchange rights, rights, warrants or options, or
otherwise; provided, however, that a Person shall not be deemed the
"Beneficial Owner" of, or to "beneficially own," (A) securities
issuable upon exercise of Rights at any time prior to the occurrence of
a Triggering Event, or (B) securities issuable upon exercise of Rights
from and after the occurrence of a Triggering Event which Rights were
acquired by such Person or any of such Person's Affiliates or
Associates prior to the Distribution Date or pursuant to Section 3(a)
or Section 22 hereof (the "Original Rights") or pursuant to Section
11(i) hereof in connection with an adjustment made with respect to any
Original Rights;
(ii) which such Person or any of such Person's Affiliates or
Associates, directly or indirectly, has the right to vote or dispose of
or has "beneficial ownership" of (as determined pursuant to Rule 13d-3
of the General Rules and Regulations under the Exchange Act), including
pursuant to any agreement, arrangement or understanding, whether or not
in writing; provided, however, that a Person shall not be deemed the
"Beneficial Owner" of, or to "beneficially own," any security under
this subparagraph (ii) as a result of an agreement, arrangement or
understanding to vote such security if such agreement, arrangement or
understanding: (A) arises solely from a revocable proxy given in
response to a public proxy or consent solicitation made pursuant to,
and in accordance with, the applicable provisions of the General Rules
and Regulations under the Exchange Act, and (B) is not also then
reportable by such Person on Schedule 13D under the Exchange Act (or
any comparable or successor report); or
<PAGE>
(iii) which are beneficially owned, directly or indirectly, by
any other Person (or any Affiliate or Associate thereof) with which
such Person (or any of such Person's Affiliates or Associates) has any
agreement, arrangement or understanding (whether or not in writing),
for the purpose of acquiring, holding, voting (except pursuant to a
revocable proxy as described in the proviso to subparagraph (ii) of
this paragraph (c)) or disposing of any voting securities of the
Company.
Notwithstanding anything in this definition of Beneficial Owner to the contrary,
a Person shall not be deemed the "Beneficial Owner" of, or to "beneficially
own," (A) securities acquired by participation in good faith in a firm
commitment underwriting by a Person engaged in business as an underwriter of
securities until the expiration of forty days after the date of such
acquisition; (B) securities which such Person or any of such Person's Affiliates
or Associates may acquire, does or do acquire or may be deemed to have the right
to acquire, pursuant to any merger or other acquisition agreement between the
Company and such Person (or one or more of his Affiliates or Associates) if such
agreement has been approved by the Board of Directors of the Company prior to
such Person's becoming an Acquiring Person; and (C) securities tendered pursuant
to a tender or exchange offer made by such Person or any of such Person's
Affiliates or Associates until such tendered securities are accepted for
purchase or exchange; nor shall any officer, director or employee of the Company
or a subsidiary of the Company be deemed, solely by reason of such Person's
status or authority as such, to be the "Beneficial Owner" of any securities that
are "beneficially owned" including, without limitation, in a fiduciary capacity,
by the Company, any Subsidiary of the Company, any employee benefit plan of the
Company or any Subsidiary of the Company or any Person or entity organized,
appointed or established by the Company for or pursuant to the terms of such
plan or by any other such officer, director or employee of the Company, any
Subsidiary of the Company, any employee benefit plan of the Company or any
Subsidiary of the Company or any Person or entity organized, appointed or
established by the Company for or pursuant to the terms of such plan.
<PAGE>
(d) "Business Day" shall mean any day other than a Saturday, Sunday or
a day on which banking institutions in the State of Georgia are authorized or
obligated by law or executive order to close.
(e) "Close of Business" on any given date shall mean 5:00 P.M., Atlanta
time, on such date; provided, however, that if such date is not a Business Day
it shall mean 5:00 P.M., Atlanta time, on the next succeeding Business Day.
(f) "Common Stock" shall mean the common stock, par value $0.01 per
share, of the Company, except that "Common Stock" when used with reference to
any Person other than the Company shall mean the capital stock of such Person
with the greatest voting power, or the equity securities or other equity
interest having power to control or direct the management of such Person.
(g) "Person" shall mean any individual, firm, corporation, partnership
or other entity.
(h) "Section 11(a)(ii) Event" shall mean any event described in Section
11(a)(ii) (A), (B) or (C) hereof. (i) "Section 13 Event" shall mean any event
described in clauses (x), (y) or (z) of Section 13(a) hereof.
(j) "Stock Acquisition Date" shall mean the first date of public
announcement (which, for purposes of this definition, shall include, without
limitation, a report filed under the Exchange Act) by the Company or an
Acquiring Person that an Acquiring Person has become such.
(k) "Subsidiary" shall mean, with reference to any Person, any
corporation of which an amount of voting securities sufficient to elect at least
a majority of the directors of such corporation is beneficially owned, directly
or indirectly, by such Person, or otherwise controlled by such Person.
(l) "Triggering Event" shall mean any Section 11(a)(ii) Event or any
Section 13 Event.
<PAGE>
Notwithstanding anything to the contrary contained in this Agreement, the
consummation of the transactions contemplated and expressly permitted by the
Purchase Agreement or Section 3.2 (a), (b) or (c) of the Standstill Agreement
shall not constitute a Triggering Event, except that if any Investor (or any
Permitted Transferee) acquires Matria Voting Securities (as defined in the
Standstill Agreement) other than in an acquisition expressly permitted by
Section 3.2(a), (b) or (c) of the Standstill Agreement, such Matria Voting
Securities, together with all other Matria Voting Securities then Beneficially
Owned by such Investor (or such Investor's Permitted Transferees), shall be
counted in determining whether a Triggering Event has occurred.
Section 2. Appointment of Rights Agent. The Company hereby appoints the
Rights Agent to act as agent for the Company and the holders of the Rights (who,
in accordance with Section 3 hereof, shall prior to the Distribution Date also
be the holders of the Common Stock) in accordance with the terms and conditions
hereof, and the Rights Agent hereby accepts such appointment. The Company may
from time to time appoint such Co-Rights Agents as it may deem necessary or
desirable.
Section 3. Issue of Rights Certificates. (a) Until the earlier of (i)
the close of business on the tenth day after the Stock Acquisition Date or (ii)
at such time as the Board of Directors of the Company may designate after the
date that a tender or exchange offer by any Person (other than the Company, any
Subsidiary of the Company, any employee benefit plan of the Company or of any
Subsidiary of the Company, or any Person or entity organized, appointed or
established by the Company for or pursuant to the terms of any such plan) is
first published or sent or given within the meaning of Rule 14d-2(a) of the
General Rules and Regulations under the Exchange Act, if upon consummation
thereof, such Person would be the Beneficial Owner of 20% or more of the shares
of Common Stock then outstanding (the earlier of (i) and (ii), as either of such
periods may be extended pursuant to the provisions of Section 27 hereof, being
herein referred to as the "Distribution Date"), (x) the Rights will be evidenced
(subject to the provisions of paragraph (b) of this Section 3) by the
certificates for the Common Stock registered in the names of the holders of the
Common Stock (which certificates for Common Stock shall be deemed also to be
certificates for Rights) and not by separate certificates, and (y) the Rights
will be transferable only in connection with the transfer of the underlying
shares of Common Stock (including a transfer to the Company). As soon as
practicable after the Distribution Date, the Rights Agent will send by
first-class, insured, postage prepaid mail, to each record holder of the Common
Stock as of the close of business on the Distribution Date, at the address of
such holder shown on the records of the Company, one or more right certificates,
in substantially the form of Exhibit A hereto (the "Rights Certificates"),
evidencing one Right for each share of Common Stock so held, subject to
adjustment as provided herein. In the event that an adjustment in the number of
Rights per share of Common Stock has been made pursuant to Section 11(p) hereof,
at the time of distribution of the Rights Certificates, the Company may make the
necessary and appropriate rounding adjustments (in accordance with Section 14(a)
hereof) so that Rights Certificates representing only whole numbers of Rights
are distributed and cash is paid in lieu of any fractional Rights. As of and
after the Distribution Date, the Rights will be evidenced solely by such Rights
Certificates.
<PAGE>
(b) With respect to certificates for the Common Stock outstanding as of
the Effective Time, until the Distribution Date, the Rights will be evidenced
by such certificates for the Common Stock and the registered holders of the
Common Stock shall also be the registered holders of the associated Rights.
Until the earlier of the Distribution Date or the Expiration Date (as such
term is defined in Section 7 hereof), the transfer of any certificates
representing shares of Common Stock in respect of which Rights have been
issued shall also constitute the transfer of the Rights associated with such
shares of Common Stock.
(c) Rights shall be issued in respect of all shares of Common Stock
which are issued after the Effective Time but prior to the earlier of the
Distribution Date or the Expiration Date. Certificates representing such
shares of Common Stock shall also be deemed to be certificates for Rights, and
Shall bear the following legend:
This certificate also evidences and entitles the holder hereof to
certain Rights as set forth in the Amended and Restated Rights Agreement
between Matria Healthcare, Inc. (the "Company") and SunTrust Bank, Atlanta
(the "Rights Agent"),dated as of April 27, 1999, as amended from time to
time (the "Rights Agreement"), the terms of which are hereby incorporated
herein by reference and a copy of which is on file at the principal
offices of the Company. Under certain circumstances, as set forth in the
Rights Agreement, such Rights will be evidenced by separate certificates
and will no longer be evidenced by this certificate. The Company will mail
to the holder of this certificate a copy of the Rights Agreement, as in
effect on the date of mailing, without charge promptly after receipt of a
written request therefor. UNDER CERTAIN CIRCUMSTANCES SET FORTH IN THE
RIGHTS AGREEMENT, RIGHTS ISSUED TO, OR HELD BY, ANY PERSON WHO IS, WAS OR
BECOMES AN ACQUIRING PERSON OR ANY AFFILIATE OR ASSOCIATE THEREOF (AS SUCH
TERMS ARE DEFINED IN THE RIGHTS AGREEMENT), WHETHER CURRENTLY HELD BY OR
ON BEHALF OF SUCH PERSON OR BY ANY SUBSEQUENT HOLDER, MAY BECOME NULL AND
VOID.
<PAGE>
With respect to such certificates containing the foregoing legend, until the
earlier of (i) the Distribution Date or (ii) the Expiration Date, the Rights
associated with the Common Stock represented by such certificates shall be
evidenced by such certificates alone and registered holders of Common Stock
shall also be the registered holders of the associated Rights, and the transfer
of any of such certificates shall also constitute the transfer of the Rights
associated with the Common Stock represented by such certificates.
Section 4. Form of Rights Certificates. (a) The Rights Certificates
(and the forms of election to purchase and of assignment to be printed on the
reverse thereof) shall each be substantially in the form set forth in Exhibit A
hereto and may have such marks of identification or designation and such
legends, summaries or endorsements printed thereon as the Company may deem
appropriate and as are not inconsistent with the provisions of this Agreement,
or as may be required to comply with any applicable law or with any rule or
regulation made pursuant thereto or with any rule or regulation of any stock
exchange on which the Rights may from time to time be listed, or to conform to
usage. Subject to the provisions of Section 11 and Section 22 hereof, the Rights
Certificates, whenever distributed, shall be dated as of the Effective Time and
on their face shall entitle the holders thereof to purchase such number of one
one-hundredths of a share of Common Stock as shall be set forth therein at the
price set forth therein (such exercise price per one one-hundredth of a share,
the "Purchase Price"), but the amount and type of securities purchasable upon
the exercise of each Right and the Purchase Price thereof shall be subject to
adjustment as provided herein.
(b) Any Rights Certificate issued pursuant to Section 3(a) or Section
22 hereof that represents Rights beneficially owned by: (i) an Acquiring Person
or any Associate or Affiliate of an Acquiring Person, (ii) a transferee of an
Acquiring Person (or of any such Associate or Affiliate) who becomes a
transferee after the Acquiring Person becomes such, or (iii) a transferee of an
Acquiring Person (or of any such Associate or Affiliate) who becomes a
transferee prior to or concurrently with the Acquiring Person becoming such and
receives such Rights pursuant to either (A) a transfer (whether or not for
consideration) from the Acquiring Person to holders of equity interests in such
Acquiring Person or to any Person with whom such Acquiring Person has any
continuing agreement, arrangement or understanding regarding the transferred
Rights or (B) a transfer which the Board of Directors of the Company has
determined is part of a plan, arrangement or understanding which has as a
primary purpose or effect avoidance of Section 7(e) hereof, and any Rights
Certificate issued pursuant to Section 6 or Section 11 hereof upon transfer,
exchange, replacement or adjustment of any other Rights Certificate referred to
in this sentence, shall contain (to the extent feasible) the following legend:
<PAGE>
The Rights represented by this Rights Certificate are or were
beneficially owned by a Person who was or became an Acquiring Person or
an Affiliate or Associate of an Acquiring Person (as such terms are
defined in the Rights Agreement). Accordingly, this Rights Certificate
and the Rights represented hereby may become null and void in the
circumstances specified in Section 7(e) of the Rights Agreement.
Section 5. Countersignature and Registration. (a) The Rights
Certificates shall be executed on behalf of the Company by its Chairman of the
Board, its President or any Vice President, either manually or by facsimile
signature, and shall have affixed thereto the Company's seal or a facsimile
thereof which shall be attested by the Secretary or an Assistant Secretary of
the Company, either manually or by facsimile signature. The Rights Certificates
shall be manually countersigned by the Rights Agent and shall not be valid for
any purpose unless so countersigned. In case any officer of the Company who
shall have signed any of the Rights Certificates shall cease to be such officer
of the Company before countersignature by the Rights Agent and issuance and
delivery by the Company, such Rights Certificates, nevertheless, may be
countersigned by the Rights Agent and issued and delivered by the Company with
the same force and effect as though the person who signed such Rights
Certificates had not ceased to be such officer of the Company, and any Rights
Certificates may be signed on behalf of the Company by any person who, at the
actual date of the execution of such Rights Certificate, shall be a proper
officer of the Company to sign such Rights Certificate, although at the date of
the execution of this Agreement any such person was not such an officer.
(b) Following the Distribution Date, the Rights Agent will keep or
cause to be kept, at its principal office or offices designated as the
appropriate place for surrender of Rights Certificates upon exercise or
transfer, books for registration and transfer of the Rights Certificates issued
hereunder. Such books shall show the names and addresses of the respective
holders of the Rights Certificates, the number of Rights evidenced on its face
by each of the Rights Certificates and the date of each of the Rights
Certificates.
<PAGE>
Section 6. Transfer, Split Up, Combination and Exchange of Rights
Certificates; Mutilated, Destroyed, Lost or Stolen Rights Certificates. (a)
Subject to the provisions of Section 4(b), Section 7(e) and Section 14 hereof,
at any time after the close of business on the Distribution Date, and at or
prior to the close of business on the Expiration Date, any Rights Certificate or
Certificates may be transferred, split up, combined or exchanged for
another Rights Certificate or Certificates, entitling the registered holder to
purchase a like number of one one-hundredths of a share of Common Stock (or,
following a Triggering Event, full Common Stock, or other securities, cash or
other assets, as the case may be) as the Rights Certificate or Certificates
surrendered then
entitled such holder (or former holder in the case of a transfer) to purchase.
Any registered holder desiring to transfer, split up, combine or exchange any
Rights Certificate or Certificates shall make such request in writing delivered
to the Rights Agent, and shall surrender the Rights Certificate or Certificates
to be transferred, split up, combined or exchanged at the principal office or
offices of the Rights Agent designated for such purpose. Neither the Rights
Agent nor the Company shall be obligated to take any action whatsoever with
respect to the transfer of any such surrendered Rights Certificate until the
registered holder shall have completed and signed the Certificate contained in
the form of assignment on the reverse side of such Rights Certificate and shall
have provided such additional evidence of the identity of the Beneficial Owner
(or former Beneficial Owner) or Affiliates or Associates thereof as the Company
shall reasonably request. Thereupon the Rights Agent shall, subject to Section
4(b), Section 7(e) and Section 14 hereof, countersign and deliver to the Person
entitled thereto a Rights Certificate or Rights Certificates, as the case may
be, as so requested. The Company may require payment of a sum sufficient to
cover any tax or governmental charge that may be imposed in connection with any
transfer, split up, combination or exchange of Rights Certificates.
<PAGE>
(b) Upon receipt by the Company and the Rights Agent of evidence
reasonably satisfactory to them of the loss, theft, destruction or mutilation
of a Rights Certificate, and, in case of loss, theft or destruction, of
indemnity or security reasonably satisfactory to them, and reimbursement to
the Company and the Rights Agent of all reasonable expenses incidental
thereto, and upon surrender to the Rights Agent and cancellation of the Rights
Certificate if mutilated, the Company will execute and deliver a new Rights
Certificate of like tenor to the Rights Agent for countersignature and
delivery to the registered owner in lieu of the Rights Certificate so lost,
stolen, destroyed or mutilated.
Section 7. Exercise of Rights; Purchase Price; Expiration Date of
Rights. (a) Subject to Section 7(e) hereof, the registered holder of any Rights
Certificate may exercise the Rights evidenced thereby (except as otherwise
provided herein including, without limitation, the restrictions on
exercisability set forth in Section 9(c), Section 11(a)(iii) and Section 23(a)
hereof) in whole or in part at any time after the Distribution Date upon
surrender of the Rights Certificate, with the form of election to purchase and
the certificate on the reverse side thereof duly executed, to the Rights Agent
at the principal office or offices of the Rights Agent designated for such
purpose, together with payment of the aggregate Purchase Price with respect to
the total number of one one-hundredths of a share (or other securities, cash or
other assets, as the case may be) as to which such surrendered Rights are then
exercisable, at or prior to the earlier of (i) the close of business on January
30, 2006 (the "Final Expiration Date"), (ii) the time at which the Rights are
redeemed as provided in Section 23 hereof or (iii) the time at which the Rights
are exchanged as provided in Section 24 hereof (the earlier of (i), (ii) and
(iii) being herein referred to as the "Expiration Date").
(b) The Purchase Price for each one one-hundredth of a share of Common
Stock pursuant to the exercise of a Right shall initially be $.61, and shall be
subject to adjustment from time to time as provided in Sections 11 and 13(a)
hereof and shall be payable in accordance with paragraph (c) below.
<PAGE>
(c) Upon receipt of a Rights Certificate representing exercisable
Rights, with the form of election to purchase and the certificate duly executed,
accompanied by payment, with respect to each Right so exercised, of the Purchase
Price per one one-hundredth of a share of Common Stock (or other shares,
securities, cash or other assets, as the case may be) to be purchased as set
forth below and an amount equal to any applicable transfer tax, the Rights Agent
shall, subject to Section 20(k) hereof, thereupon promptly (i) (A) requisition
from any transfer agent of the shares of Common Stock (or make available, if the
Rights Agent is the transfer agent for such shares) certificates for the total
number of one one-hundredths of a share of Common Stock to be Purchased, and the
Company hereby irrevocably authorizes its transfer agent to comply with all such
requests, or (B) if the Company shall have elected to deposit the total number
of shares of Common Stock issuable upon exercise of the Rights hereunder with a
depositary agent, requisition from the depositary agent depositary receipts
representing such number of one one-hundredths of a share of Common Stock as are
to be purchased (in which case certificates for the shares of Common Stock
represented by such receipts shall be deposited by the transfer agent with the
depositary agent) and the Company will direct the depositary agent to comply
with such request, (ii) requisition from the Company the amount of cash, if any,
to be paid in lieu of fractional shares in accordance with Section 14 hereof,
(iii) after receipt of such certificates or depositary receipts, cause the same
to be delivered to or upon the order of the registered holder of such Rights
Certificate, registered in such name or names as may be designated by such
holder, and (iv) after receipt thereof, deliver such cash, if any, to or upon
the order of the registered holder of such Rights Certificate. The payment of
the Purchase Price (as such amount may be reduced pursuant to Section 11(a)(iii)
hereof) shall be made in cash or by certified bank check or bank draft payable
to the order of the Company. In the event that the Company is obligated to issue
other securities (including Common Stock) of the Company, pay cash and/or
distribute other property pursuant to Section 11(a) hereof, the Company will
make all arrangements necessary so that such other securities, cash and/or other
property are available for distribution by the Rights Agent, if and when
appropriate.
(d) In case the registered holder of any Rights Certificate shall
exercise less than all the Rights evidenced thereby, a new Rights Certificate
evidencing Rights equivalent to the Rights remaining unexercised shall be issued
by the Rights Agent and delivered to, or upon the order of, the registered
holder of such Rights Certificate, registered in such name or names as may be
designated by such holder, subject to the provisions of Section 14 hereof.
(e) Notwithstanding anything in this Agreement to the contrary, from
and after the first occurrence of a Triggering Event, any Rights beneficially
owned by (i) an Acquiring Person or an Associate or Affiliate of an Acquiring
Person, (ii) a transferee of an Acquiring Person (or of any such Associate or
Affiliate) who becomes a transferee after the Acquiring Person becomes such, or
(iii) a transferee of an Acquiring Person (or of any such Associate or
Affiliate) who becomes a transferee prior to or concurrently with the Acquiring
Person becoming such and receives such Rights pursuant to either (A) a transfer
(whether or not for consideration) from the Acquiring Person to holders of
equity interests in such Acquiring Person or to any Person with whom the
Acquiring Person has any continuing agreement, arrangement or understanding
regarding the transferred Rights or (B) a transfer which the Board of Directors
of the Company has determined is part of a plan, arrangement or understanding
which has as a primary purpose or effect the avoidance of this Section 7(e),
shall become null and void without any further action and no holder of such
Rights shall have any rights whatsoever with respect to such Rights, whether
under any provision of this Agreement or otherwise. The Company shall use all
reasonable efforts to insure that the provisions of this Section 7(e) and
Section 4(b) hereof are complied with, but shall have no liability to any holder
of Rights Certificates or other Person as a result of its failure to make any
determinations with respect to an Acquiring Person or its Affiliates, Associates
or transferees hereunder.
<PAGE>
(f) Notwithstanding anything in this Agreement to the contrary, neither
the Rights Agent nor the Company shall be obligated to undertake any action with
respect to a registered holder upon the occurrence of any purported exercise as
set forth in this Section 7 unless such registered holder shall have (i)
completed and signed the certificate contained in the form of election to
purchase set forth on the reverse side of the Rights Certificate surrendered for
such exercise, and (ii) provided such additional evidence of the identity of the
Beneficial Owner (or former Beneficial Owner) or Affiliates or Associates
thereof as the Company shall reasonably request.
Section 8. Cancellation and Destruction of Rights Certificates. All
Rights Certificates surrendered for the purpose of exercise, transfer, split up,
combination or exchange shall, if surrendered to the Company or any of its
agents, be delivered to the Rights Agent for cancellation or in cancelled form,
or, if surrendered to the Rights Agent, shall be cancelled by it, and no Rights
Certificates shall be issued in lieu thereof except as expressly permitted by
any of the provisions of this Agreement. The Company shall deliver to the Rights
Agent for cancellation and retirement, and the Rights Agent shall so cancel and
retire, any other Rights Certificate purchased or acquired by the Company
otherwise than upon the exercise thereof. The Rights Agent shall deliver all
cancelled Rights Certificates to the Company, or shall, at the written request
of the Company, destroy such cancelled Rights Certificates, and in such case
shall deliver a certificate of destruction thereof to the Company.
Section 9. Reservation and Availability of Capital Stock. (a) The
Company covenants and agrees that it will cause to be reserved and kept
available out of its authorized and unissued shares of Common Stock (and,
following the occurrence of a Triggering Event, out of its authorized and
unissued shares of Common Stock and/or other securities or out of its authorized
and issued shares held in its treasury), the number of shares of Common Stock
(and/or other securities) that, as provided in this Agreement including Section
11(a)(iii) hereof, will be sufficient to permit the exercise in full of all
outstanding Rights.
<PAGE>
(b) So long as the shares of Common Stock (and, following the
occurrence of a Triggering Event, Common Stock and/or other securities) issuable
and deliverable upon the exercise of the Rights may be listed on any national
securities exchange or automated quotation system, the Company shall use its
best efforts to cause, from and after such time as the Rights become
exercisable, all shares reserved for such issuance to be listed on such exchange
or system upon official notice of issuance upon such exercise.
(c) The Company shall use its best efforts to (i) file, as soon as
practicable following the earliest date after the first occurrence of a Section
11(a)(ii) Event on which the consideration to be delivered by the Company upon
exercise of the Rights has been determined in accordance with Section 11(a)(iii)
hereof, or as soon as is required by law following the Distribution Date, as the
case may be, a registration statement under the Securities Act of 1933 (the
"Act"), with respect to the securities purchasable upon exercise of the Rights
on an appropriate form, (ii) cause such registration statement to become
effective as soon as practicable after such filing, and (iii) cause such
registration statement to remain effective (with a prospectus at all times
meeting the requirements of the Act) until the earlier of (A) the date as of
which the Rights are no longer exercisable for such securities, and (B) the date
of the expiration of the Rights. The Company will also take such action as may
be appropriate under, or to ensure compliance with, the securities or "blue sky"
laws of the various states in connection with the exercisability of the Rights.
The Company may temporarily suspend, for a period of time not to exceed ninety
(90) days after the date set forth in clause (i) of the first sentence of this
Section 9(c), the exercisability of the Rights in order to prepare and file such
registration statement and permit it to become effective. Upon any such
suspension, the Company shall issue a public announcement stating that the
exercisability of the Rights has been temporarily suspended, as well as a public
announcement at such time as the suspension is no longer in effect.
Notwithstanding any provision of this Agreement to the contrary, the Rights
shall not be exercisable in any jurisdiction unless the requisite qualification
in such jurisdiction shall have been obtained.
(d) The Company covenants and agrees that it will take all such action
as may be necessary to ensure that all one one-hundredths of a share of Common
Stock (and, following the occurrence of a Triggering Event, Common Stock and/or
other securities) delivered upon exercise of Rights shall, at the time of
delivery of the certificates for such shares (subject to payment of the Purchase
Price), be duly and validly authorized and issued and fully paid and
non-assessable.
(e) The Company further covenants and agrees that it will pay when due
and payable any and all federal and state transfer taxes and charges which may
be payable in respect of the issuance or delivery of the Rights Certificates and
of any certificates for a number of one one-hundredths of a share of Common
Stock (or Common Stock and/or other securities, as the case may be) upon the
exercise of Rights. The Company shall not, however, be required to pay any
transfer tax which may be payable in respect of any transfer or delivery of
Rights Certificates to a Person other than, or the issuance or delivery of a
number of one one-hundredths of a share of Common Stock (or Common Stock and/or
other securities, as the case may be) in respect of a name other than that of,
the registered holder of the Rights Certificates evidencing Rights surrendered
for exercise, or to issue or deliver any certificates for a number of one
one-hundredths of a share of Common Stock (or Common Stock and/or other
securities, as the case may be) in a name other than that of the registered
holder upon the exercise of any Rights until such tax shall have been paid (any
such tax being payable by the holder of such Rights Certificate at the time of
surrender) or until it has been established to the Company's satisfaction that
no such tax is due.
<PAGE>
Section 10. Common Stock Record Date. Each person in whose name any
certificate for a number of one one-hundredths of a share of Common Stock (or
full shares of Common Stock and/or other securities, as the case may be) is
issued upon the exercise of Rights shall for all purposes be deemed to have
become the holder of record of such fractional shares of Common Stock (or Common
Stock and/or other securities, as the case may be) represented thereby on, and
such certificate shall be dated, the date upon which the Rights Certificate
evidencing such Rights was duly surrendered and payment of the Purchase Price
(and all applicable transfer taxes) was made; provided, however, that if the
date of such surrender and payment is a date upon which the Common Stock (or
Common Stock and/or other securities, as the case may be) transfer books of the
Company are closed, such Person shall be deemed to have become the record holder
of such shares (fractional or otherwise) on, and such certificate shall be
dated, the next succeeding Business Day on which the Common Stock (or Common
Stock and/or other securities, as the case may be) transfer books of the Company
are open. Prior to the exercise of the Rights evidenced thereby, the holder of a
Rights Certificate shall not be entitled to any rights of a stockholder of the
Company with respect to shares for which the Rights shall be exercisable,
including, without limitation, the right to vote, to receive dividends or other
distributions or to exercise any preemptive rights, and shall not be entitled to
receive any notice of any proceedings of the Company, except as provided herein.
Section 11. Adjustment of Purchase Price, Number and Kind of Shares or
Number of Rights. The Purchase Price, the number and kind of shares covered by
each Right and the number of Rights outstanding are subject to adjustment from
time to time as provided in this Section 11.
(a)(i) In the event the Company shall at any time after the
date of this Agreement (A) declare a dividend on the Common Stock
payable in shares of Common Stock, (B) subdivide the outstanding Common
Stock, (C) combine the outstanding Common Stock into a smaller number
of shares, or (D) issue any shares of its capital stock in a
reclassification of the Common Stock (including any such
reclassification in connection with a consolidation or merger in which
the Company is the continuing or surviving corporation), except as
otherwise provided in this Section 11(a) and Section 7(e) hereof, the
Purchase Price in effect at the time of the record date for such
dividend or of the effective date of such subdivision, combination or
reclassification, and the number and kind of shares of Common Stock or
capital stock, as the case may be, issuable on such date, shall be
proportionately adjusted so that the holder of any Right exercised
after such time shall be entitled to receive, upon payment of the
Purchase Price then in effect, the aggregate number and kind of shares
of Common Stock or capital stock, as the case may be, which, if such
Right had been exercised immediately prior to such date and at a time
when the Common Stock transfer books of the Company were open, he would
have owned upon such exercise and been entitled to receive by virtue of
such dividend, subdivision, combination or reclassification; provided,
however, that in no event shall the consideration to be paid upon the
exercise of one Right be less than the aggregate par value of the
shares of Common Stock of the Company issuable upon the exercise of one
Right. If an event occurs which would require an adjustment under both
this Section 11(a)(i) and Section 11(a)(ii) hereof, the adjustment
provided for in this Section 11(a)(i) shall be in addition to, and
shall be made prior to, any adjustment required pursuant to Section
11(a)(ii) hereof.
<PAGE>
(ii) In the event:
(A) any Acquiring Person or any Associate or
Affiliate of any Acquiring Person, at any time after the date
of this Agreement, directly or indirectly, (1) shall merge
into the Company or otherwise combine with the Company and
the Company shall be the continuing or surviving corporation
of such merger or combination and the Common Stock of the
Company shall remain outstanding and unchanged, (2) shall, in
one transaction or a series of transactions, transfer any
assets to the Company or to any of its Subsidiaries in
exchange (in whole or in part) for shares of Common Stock,
for shares of other equity securities of the Company, or for
securities exercisable for or convertible into shares of
equity securities of the Company (Common Stock or otherwise)
or otherwise obtain from the Company, with or without
consideration, any additional shares of such equity
securities or securities exercisable for or convertible into
shares of such equity securities (other than pursuant to a
pro rata distribution to all holders of Common Stock), (3)
shall sell, purchase, lease, exchange, mortgage, pledge,
transfer or otherwise acquire or dispose of, in one
transaction or a series of transactions, to, from or with (as
the case may be) the Company or any of its Subsidiaries,
assets on terms and conditions less favorable to the Company
than the Company would be able to obtain in arm's length
negotiation with an unaffiliated third party, other than
pursuant to a transaction set forth in Section 13(a) hereof,
(4) shall sell, purchase, lease, exchange, mortgage, pledge,
transfer or otherwise acquire or dispose of in one
transaction or a series of transactions, to, from or with (as
the case may be) the Company or any of the Company's
Subsidiaries (other than incidental to the lines of business,
if any, engaged in as of the date hereof between the Company
and such Acquiring Person or Associate or Affiliate) assets
having an aggregate fair market value of more than
$3,000,000, other than pursuant to a transaction set forth in
Section 13(a) hereof, (5) shall receive any compensation from
the Company or any of the Company's Subsidiaries other than
compensation for full-time employment as a regular employee
at rates in accordance with the Company's (or its
Subsidiaries') past practices, or (6) shall receive the
benefit, directly or indirectly (except proportionately as a
stockholder and except if resulting from a requirement of law
or governmental regulation), of any loans, advances,
guarantees, pledges or other financial assistance or any tax
credits or other tax advantage provided by the Company or any
of its Subsidiaries, or
<PAGE>
(B) any Person (other than the Company, any
Subsidiary of the Company, any employee benefit plan of the
Company or of any Subsidiary of the Company, or any Person or
entity organized, appointed or established by the Company for
or pursuant to the terms of any such plan), alone or together
with its Affiliates and Associates, shall, at any time after
the Effective Time, become the Beneficial Owner of 20% or
more of the shares of Common Stock then outstanding, other
than pursuant to any transaction set forth in Section 13(a)
hereof, or pursuant to a tender offer or an exchange offer
for all outstanding shares of Common Stock at a price and on
terms determined by the Board of Directors to be (a) at a
price which is fair to stockholders (taking into account all
factors which such members of the Board deem relevant
including, without limitation, prices which could reasonably
be achieved if the Company or its assets were sold on an
orderly basis designed to realize maximum value) and (b)
otherwise in the best interests of the Company and its
stockholders, or
(C) during such time as there is an Acquiring Person,
there shall be any reclassification of securities (including
any reverse stock split), or recapitalization of the Company,
or any merger or consolidation of the Company with any of its
Subsidiaries or any other transaction or series of
transactions involving the Company or any of its
Subsidiaries, other than a transaction or transactions to
which the provisions of Section 13(a) apply (whether or not
with or into or otherwise involving an Acquiring Person)
which has the effect, directly or indirectly, of increasing
by more than 1% the proportionate share of the outstanding
shares of any class of equity securities of the Company or
any of its Subsidiaries which is directly or indirectly
beneficially owned by any Acquiring Person or any Associate
or Affiliate of any Acquiring Person,
<PAGE>
then, promptly following five (5) days after the date of the
occurrence of an event described in Section 11(a)(ii)(B) hereof and
promptly following the occurrence of any event described in Section
11(a)(ii)(A) or (C) hereof, proper provision shall be made so that
each holder of a Right (except as provided below and in Section 7(e)
hereof) shall thereafter have the right to receive, upon exercise of a
Right at one hundred times the then current Purchase Price in
accordance with the terms of this Agreement, in lieu of a number of
one one-hundredths of a share of Common Stock, such number of full
shares of Common Stock of the Company as shall equal the result
obtained by (x) multiplying (1) one hundred times the then current
Purchase Price by (2) the then number of one one-hundredths of a share
of Common Stock for which a Right was exercisable immediately prior to
the first occurrence of a Section 11(a)(ii) Event, and (y) dividing
that product (which, following such first occurrence, shall thereafter
be referred to as the "Purchase Price" for each Right and for all
purposes of this Agreement) by 50% of the current market price
(determined pursuant to Section 11(d) hereof) per share of Common
Stock on the date of such first occurrence (such number of shares, the
"Adjustment Shares"),
(iii) In the event that the number of shares of Common Stock
which are authorized by the Company's articles of incorporation but not
outstanding or reserved for issuance for purposes other than upon
exercise of the Rights are not sufficient to permit the exercise in
full of the Rights in accordance with the foregoing subparagraph (ii)
of this Section 11(a), the Company shall: (A) determine the excess of
(1) the value of the Adjustment Shares issuable upon the exercise of a
Right (the "Current Value") over (2) the Purchase Price (such excess,
the "Spread"), and (B) with respect to each Right, make adequate
provision to substitute for the Adjustment Shares, upon payment of the
applicable Purchase Price, (1) cash, (2) a reduction in the Purchase
Price, (3) Common Stock or other equity securities of the Company
(including, without limitation, shares, or units of shares, of
preferred stock which the Board of Directors of the Company has deemed
to have the same value as shares of Common Stock (such shares of
preferred stock, "common stock equivalents")), (4) debt securities of
the Company, (5) other assets, or (6) any combination of the foregoing,
having an aggregate value equal to the Current Value, where such
aggregate value has been determined by the Board of Directors of the
Company based upon the advice of a nationally recognized investment
banking firm selected by the Board of Directors of the Company;
provided, however, if the Company shall not have made adequate
provision to deliver value pursuant to clause (B) above within thirty
(30) days following the later of (x) the first occurrence of a Section
11(a)(ii) Event and (y) the date on which the Company's right of
redemption pursuant to Section 23 expires (the later of (x) and (y)
being referred to herein as the "Section 11(a)(ii) Trigger Date"), then
the Company shall be obligated to deliver, upon the surrender for
exercise of a Right and without requiring payment of the Purchase
Price, shares of Common Stock (to the extent available) and then, if
necessary, cash, which shares and/or cash have an aggregate value equal
to the Spread. If the Board of Directors of the Company shall determine
in good faith that it is likely that sufficient additional shares of
Common Stock could be authorized for issuance upon exercise in full of
the Rights, the thirty (30) day period set forth above may be extended
to the extent necessary, but not more than ninety (90) days after the
Section 11(a)(ii) Trigger Date, in order that the Company may seek
shareholder approval for the authorization of such additional shares
(such period, as it may be extended, the "Substitution Period"). To the
extent that the Company determines that some action need be taken
pursuant to the first and/or second sentences of this Section
11(a)(iii), the Company (x) shall provide, subject to Section 7(e)
hereof, that such action shall apply uniformly to all outstanding
Rights, and (y) may suspend the exercisability of the Rights until the
<PAGE>
expiration of the Substitution Period in order to seek any
authorization of additional shares and/or to decide the appropriate
form of distribution to be made pursuant to such first sentence and to
determine the value thereof. In the event of any such suspension, the
Company shall issue a public announcement stating that the
exercisability of the Rights has been temporarily suspended, as well as
a public announcement at such time as the suspension is no longer in
effect. For purposes of this Section 11(a)(iii), the value of the
Common Stock shall be the current market price (as determined pursuant
to Section 11(d) hereof) per share of the Common Stock on the Section
11(a)(ii) Trigger Date and the value of any "common stock equivalent"
shall be deemed to have the same value as the Common Stock on such
date. (b) In case the Company shall fix a record date for the issuance
of rights, options or warrants to all holders of
Common Stock entitling them to subscribe for or purchase (for a period expiring
within forty-five (45) calendar days after such record date) Common Stock (or
shares having the same rights, privileges and preferences as the shares of
Common Stock ("equivalent common stock")) or securities convertible into Common
Stock or equivalent common stock at a price per share of Common Stock or per
share of equivalent common stock (or having a conversion price per share, if a
security convertible into Common Stock or equivalent common stock) less than the
current market price (as determined pursuant to Section 11(d) hereof) per share
of Common Stock on such record date, the Purchase Price to be in effect after
such record date shall be determined by multiplying the Purchase Price in effect
immediately prior to such record date by a fraction, the numerator of which
shall be the number of shares of Common Stock outstanding on such record date,
plus the number of shares of Common Stock which the aggregate offering price of
the total number of shares of Common Stock and/or equivalent common stock so to
be offered (and/or the aggregate initial conversion price of the convertible
securities so to be offered) would purchase at such current market price, and
the denominator of which shall be the number of shares of Common Stock
outstanding on such record date, plus the number of additional shares of Common
Stock and/or equivalent common stock to be offered for subscription or purchase
(or into which the convertible securities so to be offered are initially
convertible); provided, however, that in no event shall the consideration to be
paid upon the exercise of one Right be less than the aggregate par value of the
shares of capital stock of the Company issuable upon the exercise of one Right.
In case such subscription price may be paid by delivery of consideration part or
all of which may be in a form other than cash, the value of such consideration
shall be as determined in good faith by the Board of Directors of the Company,
whose determination shall be described in a statement filed with the Rights
Agent and shall be binding on the Rights Agent and the holders of the Rights.
Shares of Common Stock owned by or held for the account of the Company shall not
be deemed outstanding for the purpose of any such computation. Such adjustment
shall be made successively whenever such a record date is fixed, and in the
event that such rights or warrants are not so issued, the Purchase Price shall
be adjusted to be the Purchase Price which would then be in effect if such
record date had not been fixed.
<PAGE>
(c) In case the Company shall fix a record date for a distribution to
all holders of Common Stock (including any such distribution made in connection
with a consolidation or merger in which the Company is the continuing or
surviving corporation) of evidences of indebtedness, cash (other than a regular
quarterly cash dividend out of the earnings or retained earnings of the
Company), assets (other than a dividend payable in Common Stock, but including
any dividend payable in stock other than Common Stock) or subscription rights or
warrants (excluding those referred to in Section 11(b) hereof), the Purchase
Price to be in effect after such record date shall be determined by multiplying
the Purchase Price in effect immediately prior to such record date by a
fraction, the numerator of which shall be the current market price (as
determined pursuant to Section 11(d) hereof) per share of Common Stock on such
record date, less the fair market value (as determined in good faith by the
Board of Directors of the Company, whose determination shall be described in a
statement filed with the Rights Agent) of the portion of the cash, assets or
evidences of indebtedness so to be distributed or of such subscription rights or
warrants applicable to a share of Common Stock and the denominator of which
shall be such current market price (as determined pursuant to Section 11(d)
hereof) per share of Common Stock; provided, however, that in no event shall the
consideration to be paid upon the exercise of one Right be less than the
aggregate par value of the shares of capital stock of the Company issuable upon
the exercise of one Right. Such adjustments shall be made successively whenever
such a record date is fixed, and in the event that such distribution is not so
made, the Purchase Price shall be adjusted to be the Purchase Price which would
have been in effect if such record date had not been fixed.
(d) For the purpose of any computation hereunder, other than
computations made pursuant to Section 11(a)(iii) hereof, the "current market
price" per share of Common Stock on any date shall be deemed to be the average
of the daily closing prices per share of such Common Stock for the thirty (30)
consecutive Trading Days (as such term is hereinafter defined) immediately prior
to such date, and for purposes of computations made pursuant to Section
11(a)(iii) hereof, the "current market price" per share of Common Stock on any
date shall be deemed to be the average of the daily closing prices per share of
such Common Stock for the ten (10) consecutive Trading Days immediately
following such date; provided, however, that in the event that the current
market price per share of the Common Stock is determined during a period
following the announcement by the issuer of such Common Stock of (A) a dividend
or distribution on such Common Stock payable in shares of such Common Stock or
securities convertible into shares of such Common Stock (other than the Rights),
or (B) any subdivision, combination or reclassification of such Common Stock,
<PAGE>
and prior to the expiration of the requisite thirty (30) Trading Day or ten (10)
Trading Day period, as set forth above, after the ex-dividend date for such
dividend or distribution, or the record date for such subdivision, combination
or reclassification, then, and in each such case, the "current market price"
shall be properly adjusted to take into account ex-dividend trading. The closing
price for each day shall be the last sale price, regular way, or, in case no
such sale takes place on such day, the average of the closing bid and asked
prices, regular way, in either case as reported in the principal consolidated
transaction reporting system with respect to securities listed or admitted to
trading on the New York Stock Exchange or, if the shares of Common Stock are not
listed or admitted to trading on the New York Stock Exchange, as reported in the
principal consolidated transaction reporting system with respect to securities
listed on the principal national securities exchange on which the shares of
Common Stock are listed or admitted to trading or, if the shares of Common Stock
are not listed or admitted to trading on any national securities exchange, the
last quoted price or, if not so quoted, the average of the high bid and low
asked prices in the over-the-counter market, as reported by the National
Association of Securities Dealers, Inc. Automated Quotation System ("NASDAQ") or
such other system then in use, or, if on any such date the shares of Common
Stock are not quoted by any such organization, the average of the closing bid
and asked prices as furnished by a professional market maker making a market in
the Common Stock selected by the Board of Directors of the Company. If on any
such date no market maker is making a market in the Common Stock, the fair value
of such shares on such date as determined in good faith by the Board of
Directors of the Company shall be used. The term "Trading Day" shall mean a day
on which the principal national securities exchange on which the shares of
Common Stock are listed or admitted to trading is open for the transaction of
business or, if the shares of Common Stock are not listed or admitted to trading
on any national securities exchange, a Business Day. If the Common Stock is not
publicly held or not so listed or traded, "current market price" per share shall
mean the fair value per share as determined in good faith by the Board of
Directors of the Company, whose determination shall be described in a statement
filed with the Rights Agent and shall be conclusive for all purposes. For all
purposes of this Agreement, the "current market price" of one one-hundredth of a
share of Common Stock shall be equal to the "current market price" of one share
of Common Stock divided by 100.
<PAGE>
(e) Anything herein to the contrary notwithstanding, no adjustment in
the Purchase Price shall be required unless such adjustment would require an
increase or decrease of at least one percent (1%) in the Purchase Price;
provided, however, that any adjustments which by reason of this Section 11(e)
are not required to be made shall be carried forward and taken into account in
any subsequent adjustment. All calculations under this Section 11 shall be made
to the nearest cent or to the nearest ten-thousandth of a share of Common Stock.
Notwithstanding the first sentence of this Section 11(e), any adjustment
required by this Section 11 shall be made no later than the earlier of (i) three
(3) years from the date of the transaction which mandates such adjustment, or
(ii) the Expiration Date.
(f) If as a result of an adjustment made pursuant to Section 11(a)(ii)
or Section 13(a) hereof, the holder of any Right thereafter exercised shall
become entitled to receive any shares of capital stock other than Common Stock,
thereafter the number of such other shares so receivable upon exercise of any
Right and the Purchase Price thereof shall be subject to adjustment from time to
time in a manner and on terms as nearly equivalent as practicable to the
provisions with respect to the Common Stock contained in Sections 11(a), (b),
(c), (e), (g), (h), (i), (j),(k) and (m), and the provisions of Sections 7, 9,
10, 13 and 14 hereof with respect to the Common Stock shall apply on like terms
to any such other shares.
(g) All Rights originally issued by the Company subsequent to any
adjustment made to the Purchase Price hereunder shall evidence the right to
purchase, at the adjusted Purchase Price, the number of one one-hundredths of a
share of Common Stock purchasable from time to time hereunder upon exercise of
the Rights, all subject to further adjustment as provided herein.
(h) Unless the Company shall have exercised its election as provided in
Section 11(i), upon each adjustment of the Purchase Price as a result of the
calculations made in Sections 11(b) and (c), each Right outstanding immediately
prior to the making of such adjustment shall thereafter evidence the right to
purchase, at the adjusted Purchase Price, that number of one one-hundredths of a
share of Common Stock (calculated to the nearest ten-thousandth) obtained by (i)
multiplying (x) the number of one one-hundredths of a share covered by a Right
immediately prior to this adjustment, by (y) the Purchase Price in effect
immediately prior to such adjustment of the Purchase Price, and (ii) dividing
the product so obtained by the Purchase Price in effect immediately after such
adjustment of the Purchase Price.
<PAGE>
(i) The Company may elect on or after the date of any adjustment of the
Purchase Price to adjust the number of Rights, in lieu of any adjustment in the
number of one one-hundredths of a share of Common Stock purchasable upon the
exercise of a Right. Each of the Rights outstanding after the adjustment in the
number of Rights shall be exercisable for the number of one one-hundredths of a
share of Common Stock for which a Right was exercisable immediately prior to
such adjustment. Each Right held of record prior to such adjustment of the
number of Rights shall become that number of Rights (calculated to the nearest
one-ten-thousandth) obtained by dividing the Purchase Price in effect
immediately prior to adjustment of the Purchase Price by the Purchase Price in
effect immediately after adjustment of the Purchase Price. The Company shall
make a public announcement of its election to adjust the number of Rights,
indicating the record date for the adjustment, and, if known at the time, the
amount of the adjustment to be made. This record date may be the date on which
the Purchase Price is adjusted or any day thereafter, but, if the Rights
Certificates have been issued, shall be at least ten (10) days later than the
date of the public announcement. If Rights Certificates have been issued, upon
each adjustment of the number of Rights pursuant to this Section 11(i), the
Company shall, as promptly as practicable, cause to be distributed to holders of
record of Rights Certificates on such record date Rights Certificates
evidencing, subject to Section 14 hereof, the additional Rights to which such
holders shall be entitled as a result of such adjustment, or, at the option of
the Company, shall cause to be distributed to such holders of record in
substitution and replacement for the Rights Certificates held by such holders
prior to the date of adjustment, and upon surrender thereof, if required by the
Company, new Rights Certificates evidencing all the Rights to which such holders
shall be entitled after such adjustment. Rights Certificates to be so
distributed shall be issued, executed and countersigned in the manner provided
for herein (and may bear, at the option of the Company, the adjusted Purchase
Price) and shall be registered in the names of the holders of record of Rights
Certificates on the record date specified in the public announcement.
(j) Irrespective of any adjustment or change in the Purchase Price or
the number of one one-hundredths of a share of Common Stock issuable upon the
exercise of the Rights, the Rights Certificates theretofore and thereafter
issued may continue to express the Purchase Price per one one-hundredth of a
share and the number of one one-hundredths of a share which were expressed in
the initial Rights Certificates issued hereunder.
<PAGE>
(k) Before taking any action that would cause an adjustment reducing
the Purchase Price below the then stated value, if any, of the number of one
one-hundredths of a share of Common Stock issuable upon exercise of the Rights,
the Company shall take any corporate action which may, in the opinion of its
counsel, be necessary in order that the Company may validly and legally issue
fully paid and non-assessable such number of one one-hundredths of a share of
Common Stock at such adjusted Purchase Price.
(l) In any case in which this Section 11 shall require that an
adjustment in the Purchase Price be made effective as of a record date for a
specified event, the Company may elect to defer until the occurrence of such
event the issuance to the holder of any Right exercised after such record date
the number of one one-hundredths of a share of Common Stock and other capital
stock or securities of the Company, if any, issuable upon such exercise over and
above the number of one one-hundredths of a share of Common Stock and other
capital stock or securities of the Company, if any, issuable upon such exercise
on the basis of the Purchase Price in effect prior to such adjustment; provided,
however, that the Company shall deliver to such holder a due bill or other
appropriate instrument evidencing such holder's right to receive such additional
shares (fractional or otherwise) or securities upon the occurrence of the event
requiring such adjustment.
(m) Anything in this Section 11 to the contrary notwithstanding, the
Company shall be entitled to make such reductions in the Purchase Price, in
addition to those adjustments expressly required by this Section 11, as and to
the extent that in their good faith judgment the Board of Directors of the
Company shall determine to be advisable in order that any (i) consolidation or
subdivision of the Common Stock, (ii) issuance wholly for cash of any shares of
Common Stock at less than the current market price, (iii) issuance wholly for
cash of shares of Common Stock or securities which by their terms are
convertible into or exchangeable for shares of Common Stock, (iv) stock
dividends or (v) issuance of rights, options or warrants referred to in this
Section 11, hereafter made by the Company to holders of its Common Stock shall
not be taxable to such stockholders.
<PAGE>
(n) The Company covenants and agrees that it shall not, at any time
after the Distribution Date, (i) consolidate with any other Person (other than a
Subsidiary of the Company in a transaction which complies with Section 11(o)
hereof and has been approved by the Board of Directors), (ii) merge with or into
any other Person (other than a Subsidiary of the Company in a transaction which
complies with Section 11(o) hereof and has been approved by the Board of
Directors), or (iii) sell or transfer (or permit any Subsidiary to sell or
transfer), in one transaction, or a series of related transactions, assets or
earning power aggregating more than 50% of the assets or earning power of the
Company and its Subsidiaries (taken as a whole) to any other Person or Persons
(other than the Company and/or any of its Subsidiaries in one or more
transactions each of which complies with Section 11(o) hereof and has been
approved by the Board of Directors), if (x) at the time of or immediately after
such consolidation, merger or sale there are any rights, warrants or other
instruments or securities outstanding or agreements in effect which would
substantially diminish or otherwise eliminate the benefits intended to be
afforded by the Rights or (y) prior to, simultaneously with or immediately after
such consolidation, merger or sale, the shareholders of the Person who
constitutes, or would constitute, the "Principal Party" for purposes of Section
13(a) hereof shall have received a distribution of Rights previously owned by
such Person or any of its Affiliates and Associates.
(o) The Company covenants and agrees that, after the Distribution Date,
it will not, except as permitted by Section 23, Section 24 or Section 27 hereof,
take (or permit any Subsidiary to take) any action if at the time such action is
taken it is reasonably foreseeable that such action will diminish substantially
or otherwise eliminate the benefits intended to be afforded by the Rights.
<PAGE>
(p) Anything in this Agreement to the contrary notwithstanding, in the
event that the Company shall at any time after the Effective Time and prior to
the Distribution Date (i) declare a dividend on the outstanding shares of Common
Stock payable in shares of Common Stock, (ii) subdivide the outstanding shares
of Common Stock, or (iii) combine the outstanding shares of Common Stock into a
smaller number of shares, the number of Rights associated with each share of
Common Stock then outstanding, or issued or delivered thereafter but prior to
the Distribution Date or in accordance with Section 22 hereof, shall be
proportionately adjusted so that the number of Rights thereafter associated with
each share of Common Stock following any such event shall equal the result
obtained by multiplying the number of Rights associated with each share of
Common Stock immediately prior to such event by a fraction, the numerator of
which shall be the total number of shares of Common Stock outstanding
immediately prior to the occurrence of the event and the denominator of which
shall be the total number of shares of Common Stock outstanding immediately
following the occurrence of such event.
Section 12. Certificate of Adjusted Purchase Price or Number of Shares.
Whenever an adjustment is made as provided in Section 11 and Section 13 hereof,
the Company shall (a) promptly prepare a certificate setting forth such
adjustment and a brief statement of the facts accounting for such adjustment,
(b) promptly file with the Rights Agent, and with each transfer agent for the
Common Stock and the Common Stock, a copy of such certificate, and (c) mail a
brief summary thereof to each holder of a Rights Certificate (or, if prior to
the Distribution Date, to each holder of a certificate representing shares of
Common Stock) in accordance with Section 26 hereof. The Rights Agent shall be
fully protected in relying on any such certificate and on any adjustment therein
contained and shall not be deemed to have knowledge of any adjustment unless and
until it shall have received such certificate.
Section 13. Consolidation, Merger or Sale or Transfer of Assets or
Earning Power. (a) In the event that, during such time as there is an Acquiring
Person, directly or indirectly, (x) the Company shall consolidate with, or merge
with and into, any other Person (other than a Subsidiary of the Company in a
transaction which complies with Section 11(o) hereof and has been approved by
the Board of Directors), and the Company shall not be the continuing or
surviving corporation of such consolidation or merger, (y) any Person (other
than a Subsidiary of the Company in a transaction which complies with Section
11(o) hereof and has been approved by the Board of Directors) shall consolidate
with, or merge with or into, the Company, and the Company shall be the
continuing or surviving corporation of such consolidation or merger and, in
connection with such consolidation or merger, all or part of the outstanding
shares of Common Stock shall be changed into or exchanged for stock or other
securities of any other Person or cash or any other property, or (z) the Company
shall sell or otherwise transfer (or one or more of its Subsidiaries shall sell
or otherwise transfer), in one transaction or a series of related transactions,
assets or earning power aggregating 50% or more of the assets or earning power
of the Company and its Subsidiaries (taken as a whole) to any Person or Persons
(other than the Company or any Subsidiary of the Company in one or more
transactions each of which complies with Section 11(o) hereof and has been
approved by the Board of Directors), then, and in each such case, proper
provision shall be made so that: (i) each holder of a Right, except as provided
in Section 7(e) hereof, shall thereafter have the right to receive, upon the
exercise thereof at one hundred times the then current Purchase Price in
accordance with the terms of this Agreement, such number of validly authorized
and issued, fully paid, non-assessable and freely tradable full shares of Common
Stock of the Principal Party (as such term is hereinafter defined), not subject
to any liens, encumbrances, rights of first refusal or other adverse claims, as
shall be equal to the result obtained by (1) multiplying by one hundred the then
<PAGE>
current Purchase Price multiplied by the number of one-hundredths of a share of
Common Stock for which a Right is exercisable immediately prior to the first
occurrence of a Section 13 Event (or, if a Section 11(a)(ii) Event has occurred
prior to the first occurrence of a Section 13 Event, multiplying the number of
such one-hundredths of a share for which a Right was exercisable immediately
prior to the first occurrence of a Section 11(a)(ii) Event by one hundred times
the Purchase Price in effect immediately prior to such first occurrence), and
dividing that product (which, following the first occurrence of a Section 13
Event, shall be referred to as the "Purchase Price" for each Right and for all
purposes of this Agreement) by (2) 50% of the current market price (determined
pursuant to Section 11(d) hereof) per share of the Common Stock of such
Principal Party on the date of consummation of such Section 13 Event; (ii) such
Principal Party shall thereafter be liable for, and shall assume, by virtue of
such Section 13 Event, all the obligations and duties of the Company pursuant to
this Agreement; (iii) the term "Company" shall thereafter be deemed to refer to
such Principal Party, it being specifically intended that the provisions of
Section 11 hereof shall apply only to such Principal Party following the first
occurrence of a Section 13 Event; (iv) such Principal Party shall take such
steps (including, but not limited to, the reservation of a sufficient number of
shares of its Common Stock) in connection with the consummation of any such
transaction as may be necessary to assure that the provisions hereof shall
thereafter be applicable, as nearly as reasonably may be, in relation to its
shares of Common Stock thereafter deliverable upon the exercise of the Rights;
and (v) the provisions of Section 11(a)(ii) hereof shall be of no effect
following the first occurrence of any Section 13 Event.
(b) "Principal Party" shall mean
(i) in the case of any transaction described in clause (x) or
(y) of the first sentence of Section 13(a), the Person that is the
issuer of any securities into which shares of Common Stock of the
Company are converted in such merger or consolidation, and if no
securities are so issued, the Person that is the other party to such
merger or consolidation; and
(ii) in the case of any transaction described in clause (z) of
the first sentence of Section 13(a), the Person that is the party
receiving the greatest portion of the assets or earning power
transferred pursuant to such transaction or transactions; provided,
however, that in any such case, (1) if the Common Stock of such Person
is not at such time and has not been continuously over the preceding
twelve (12) month period registered under Section 12 of the Exchange
Act, and such Person is a direct or indirect Subsidiary of another
Person the Common Stock of which is and has been so registered,
"Principal Party" shall refer to such other Person; and (2) in case
such Person is a Subsidiary, directly or indirectly, of more than one
Person, the Common Stocks of two or more of which are and have been so
registered, "Principal Party" shall refer to whichever of such Persons
is the issuer of the Common Stock having the greatest aggregate market
value. (c) The Company shall not consummate any such consolidation,
merger, sale or transfer unless the Principal Party shall
have a sufficient number of authorized shares of its Common Stock which have not
been issued or reserved for issuance to permit the exercise in full of the
Rights in accordance with this Section 13 and unless prior thereto the Company
and such Principal Party shall have executed and delivered to the Rights Agent a
supplemental agreement providing for the terms set forth in paragraphs (a) and
(b) of this Section 13 and further providing that, as soon as practicable after
the date of any consolidation, merger or sale of assets mentioned in paragraph
(a) of this Section 13, the Principal Party will:
<PAGE>
(i) prepare and file a registration statement under the Act,
with respect to the Rights and the securities purchasable upon exercise
of the Rights on an appropriate form, and will use its best efforts to
cause such registration statement to (A) become effective as soon as
practicable after such filing and (B) remain effective (with a
prospectus at all times meeting the requirements of the Act) until the
Expiration Date;
(ii) use its best efforts to qualify or register the Rights
and the securities purchasable upon exercise of the Rights under the
blue sky laws of such jurisdictions as may be necessary or appropriate;
and
(iii) will deliver to holders of the Rights historical
financial statements for the Principal Party and each of its Affiliates
which comply in all respects with the requirements for registration on
Form 10 under the Exchange Act.
The provisions of this Section 13 shall similarly apply to successive mergers or
consolidations or sales or other transfers. In the event that a Section 13 Event
shall occur at any time after the occurrence of a Section 11(a)(ii) Event, the
Rights which have not theretofore been exercised shall thereafter become
exercisable in the manner described in Section 13(a).
(d) Notwithstanding anything in this Agreement to the contrary, Section
13 shall not be applicable to a transaction described in subparagraphs (x) and
(y) of Section 13(a) if (i) such transaction has been approved by the Board of
Directors of the Company; or (ii)(A) such transaction is consummated with a
Person or Persons who acquired shares of Common Stock pursuant to a tender offer
or exchange offer for all outstanding shares of Common Stock which complies with
the provisions of Section 11(a)(ii)(B) hereof (or a wholly owned subsidiary of
any such Person or Persons), (B) the price per share of Common Stock offered in
such transaction is not less than the price per share of Common Stock paid to
all holders of shares of Common Stock whose shares were purchased pursuant to
such tender offer or exchange offer, and (C) the form of consideration being
offered to the remaining holders of shares of Common Stock pursuant to such
transaction is the same as the form of consideration paid pursuant to such
tender offer or exchange offer. Upon consummation of any such transaction
contemplated by this Section 13(d), all Rights hereunder shall expire.
<PAGE>
Section 14. Fractional Rights and Fractional Shares. (a) The Company shall
not be required to issue fractions of Rights, except prior to the Distribution
Date as provided in Section 11(p) hereof, or to distribute Rights Certificates
which evidence fractional Rights. In lieu of such fractional Rights, there shall
be paid to the registered holders of the Rights Certificates with regard to
which such fractional Rights would otherwise be issuable, an amount in cash
equal to the same fraction of the current market value of a whole Right. For
purposes of this Section 14(a), the current market value of a whole Right shall
be the closing price of the Rights for the Trading Day immediately prior to the
date on which such fractional Rights would have been otherwise issuable. The
closing price of the Rights for any day shall be the last sale price, regular
way, or, in case no such sale takes place on such day, the average of the
closing bid and asked prices, regular way, in either case as reported in the
principal consolidated transaction reporting System with respect to securities
listed or admitted to trading on the New York Stock Exchange or, if the Rights
are not listed or admitted to trading on the New York Stock Exchange, as
reported in the principal consolidated transaction reporting system with respect
to securities listed on the principal national securities exchange on which the
Rights are listed or admitted to trading, or if the Rights are not listed or
admitted to trading on any national securities exchange, the last quoted price
or, if not so quoted, the average of the high bid and low asked prices in the
over-the-counter market, as reported by NASDAQ or such other system then in use
or, if on any such date the Rights are not quoted by any such organization, the
average of the closing bid and asked prices as furnished by a professional
market maker making a market in the Rights selected by the Board of Directors of
the Company. If on any such date no such market maker is making a market in the
Rights the fair value of the Rights on such date as determined in good faith by
the Board of Directors of the Company shall be used.
(b) The Company shall not be required to issue fractions of shares of
Common Stock (other than fractions which are integral multiples of one
one-hundredth of a share of Common Stock) upon exercise of the Rights or to
distribute certificates which evidence fractional shares of Common Stock (other
than fractions which are integral multiples of one one-hundredth of a share of
Common Stock); provided, however, that in lieu of fractions of shares of Common
Stock which are integral multiples of one one-hundredth of a share of Common
Stock, the Company may provide for the issuance of depositary receipts pursuant
to Section 7(c) hereof. In lieu of fractional shares of Common Stock that are
not integral multiples of one one-hundredth of a share of Common Stock, the
Company may pay to the registered holders of Rights Certificates at the time
such Rights are exercised as herein provided an amount in cash equal to the same
fraction of the current market value of one one-hundredth of a share of Common
Stock. For purposes of this Section 14(b), the current market value of one
one-hundredth of a share of Common Stock shall be one one-hundredth of the
closing price of a share of Common Stock (as determined pursuant to Section
11(d) hereof) for the Trading Day immediately prior to the date of such
exercise.
<PAGE>
(c) The holder of a Right by the acceptance of the Rights expressly
waives his right to receive any fractional Rights or any fractional shares upon
exercise of a Right, except as permitted by this Section 14.
Section 15. All Rights of Action. All rights of action in respect of
this Agreement, other than rights of action vested in the Rights Agent pursuant
to Section 18 hereof, are vested in the respective registered holders of the
Rights Certificates (and, prior to the Distribution Date, the registered holders
of the Common Stock); and any registered holder of any Rights Certificate (or,
prior to the Distribution Date, of the Common Stock), without the consent of the
Rights Agent or of the holder of any other Rights Certificate (or, prior to the
Distribution Date, of the Common Stock), may, in his own behalf and for his own
benefit, enforce, and may institute and maintain any Suit, action or proceeding
against the Company to enforce, or otherwise act in respect of, his right to
exercise the Rights evidenced by such Rights Certificate in the manner provided
in such Rights Certificate and in this Agreement. Without limiting the foregoing
or any remedies available to the holders of Rights, it is specifically
acknowledged that the holders of Rights would not have an adequate remedy at law
for any breach of this Agreement and shall be entitled to specific performance
of the obligations hereunder and injunctive relief against actual or threatened
violations of the obligations hereunder of any Person subject to this Agreement.
Section 16. Agreement of Rights Holders. Every holder of a Right by
accepting the same consents and agrees with the Company and the Rights Agent and
with every other holder of a Right that:
(a) prior to the Distribution Date, the Rights will be transferable
only in connection with the transfer of Common Stock; (b) after the
Distribution Date, the Rights Certificates are transferable only on the
registry books of the Rights Agent
if surrendered at the principal office or offices of the Rights Agent designated
for such purposes, duly endorsed or accompanied by a proper instrument of
transfer and with the appropriate forms and certificates fully executed;
(c) subject to Section 6(a) and Section 7(f) hereof, the Company and
the Rights Agent may deem and treat the person in whose name a Rights
Certificate (or, prior to the Distribution Date, the associated Common Stock
certificate) is registered as the absolute owner thereof and of the Rights
evidenced thereby (notwithstanding any notations of ownership or writing on the
Rights Certificates or the associated Common Stock certificate made by anyone
other than the Company or the Rights Agent) for all purposes whatsoever, and
neither the Company nor the Rights Agent, subject to the last sentence of
Section 7(e) hereof, shall be required to be affected by any notice to the
contrary; and
<PAGE>
(d) notwithstanding anything in this Agreement to the contrary, neither
the Company nor the Rights Agent shall have any liability to any holder of a
Right or other Person as a result of its inability to perform any of its
obligations under this Agreement by reason of any preliminary or permanent
injunction or other order, decree or ruling issued by a court of competent
jurisdiction or by a governmental, regulatory or administrative agency or
commission, or any statute, rule, regulation or executive order promulgated or
enacted by any governmental authority, prohibiting or otherwise restraining
performance of such obligation; provided, however, the Company must use its best
efforts to have any such order, decree or ruling lifted or otherwise overturned
as soon as possible.
Section 17. Rights Certificate Holder Not Deemed a Stockholder. No
holder, as such, of any Rights Certificate shall be entitled to vote, receive
dividends or be deemed for any purpose the holder of the number of one
one-hundredths of a share of Common Stock or any other securities of the Company
which may at any time be issuable on the exercise of the Rights represented
thereby, nor shall anything contained herein or in any Rights Certificate be
construed to confer upon the holder of any Rights Certificate, as such, any of
the rights of a stockholder of the Company or any right to vote for the election
of directors or upon any matter submitted to stockholders at any meeting
thereof, or to give or withhold consent to any corporate action, or to receive
notice of meetings or other actions affecting stockholders (except as provided
in Section 25 hereof), or to receive dividends or subscription rights, or
otherwise, until the Right or Rights evidenced by such Rights Certificate shall
have been exercised in accordance with the provisions hereof. This Section 17
shall also apply to holders, as such, of Rights prior to the issuance of Rights
Certificates.
Section 18. Concerning the Rights Agent. (a) The Company agrees to pay
to the Rights Agent reasonable compensation for all services rendered by it
hereunder and, from time to time, on demand of the Rights Agent, its reasonable
expenses and counsel fees and disbursements and other disbursements incurred in
the administration and execution of this Agreement and the exercise and
performance of its duties hereunder. The Company also agrees to indemnify the
Rights Agent for, and to hold it harmless against, any losses, expenses, claims,
damages or liabilities, incurred without gross negligence, bad faith or willful
misconduct on the part of the Rights Agent, for anything done or omitted by the
Rights Agent in connection with the acceptance and administration of this
Agreement and performance hereunder, including, without limitation, the costs
and expenses of defending against any claim of liability arising therefrom,
directly or indirectly, and will promptly reimburse the Rights Agent for any
legal or other expenses reasonably incurred in investigating or defending any
such loss, expense, claim, damage or liability.
(b) The Rights Agent shall be protected by the indemnity provided by
this Section 18 and shall incur no liability for or in respect of any action
taken, suffered or omitted by it in connection with its administration of this
Agreement in reliance upon any Rights Certificate or certificate for Common
Stock or for other securities of the Company, instrument of assignment or
transfer, power of attorney, endorsement, affidavit, letter, notice, direction,
consent, certificate, statement, or other paper or document believed by it to be
genuine and to be signed, executed and, where necessary, verified or
acknowledged, by the proper Person or Persons.
<PAGE>
Section 19. Merger or Consolidation or Change of Name of Rights Agent.
(a) Any corporation into which the Rights Agent or any successor Rights Agent
may be merged or with which it may be consolidated, or any corporation resulting
from any merger or consolidation to which the Rights Agent or any successor
Rights Agent shall be a party, or any corporation succeeding to the corporate
trust business of the Rights Agent or any successor Rights Agent, shall be the
successor to the Rights Agent under this Agreement without the execution or
filing of any paper or any further act on the part of any of the parties hereto;
provided, however, that such corporation would be eligible for appointment as a
successor Rights Agent under the provisions of Section 21 hereof. In case at the
time such successor Rights Agent shall succeed to the agency created by this
Agreement, any of the Rights Certificates shall have been countersigned but not
delivered, any such successor Rights Agent may adopt the countersignature of a
predecessor Rights Agent and deliver such Rights Certificates so countersigned;
and in case at that time any of the Rights Certificates shall not have been
countersigned, any successor Rights Agent may countersign such Rights
Certificates either in the name of the predecessor or in the name of the
successor Rights Agent; and in all such cases such Rights Certificates shall
have the full force provided in the Rights Certificates and in this Agreement.
(b) In case at any time the name of the Rights Agent shall be changed
and at such time any of the Rights Certificates shall have been countersigned
but not delivered, the Rights Agent may adopt the countersignature under its
prior name and deliver Rights Certificates so countersigned; and in case at that
time any of the Rights Certificates shall not have been countersigned, the
Rights Agent may countersign such Rights Certificates either in its prior name
or in its changed name; and in all such cases such Rights Certificates shall
have the full force provided in the Rights Certificates and in this Agreement.
Section 20. Duties of Rights Agent. The Rights Agent undertakes the
duties and obligations imposed by this Agreement upon the following terms and
conditions, by all of which the Company and the holders of Rights Certificates,
by their acceptance thereof, shall be bound:
(a) The Rights Agent may consult with legal counsel (who may be legal
counsel for the Company), and the opinion of such counsel shall be full and
complete authorization and protection to the Rights Agent as to any action taken
or omitted by it in good faith and in accordance with such opinion.
<PAGE>
(b) Whenever in the performance of its duties under this Agreement the
Rights Agent shall deem it necessary or desirable that any fact or matter
(including, without limitation, the identity of any Acquiring Person and the
determination of "current market price") be proved or established by the Company
prior to taking or suffering any action hereunder, such fact or matter (unless
other evidence in respect thereof be herein specifically prescribed) may be
deemed to be conclusively proved and established by a certificate signed by the
Chairman of the Board, the President, any Vice President, the Treasurer, any
Assistant Treasurer, the Secretary or any Assistant Secretary of the Company and
delivered to the Rights Agent; and such certificate shall be full authorization
to the Rights Agent for any action taken or suffered in good faith by it under
the provisions of this Agreement in reliance upon such certificate.
(c) The Rights Agent shall not be liable for or by reason of any of the
statements of fact or recitals contained in this Agreement or in the Rights
Certificates or be required to verify the same (except as to its
countersignature on such Rights Certificates), but all such statements and
recitals are and shall be deemed to have been made by the Company only.
(d) The Rights Agent shall not be under any responsibility in respect
of the validity or legality of this Agreement or the execution and delivery
hereof (except the due execution hereof by the Rights Agent) or in respect of
the validity or legality or execution of any Rights Certificate (except its
countersignature thereof); nor shall it be responsible for any breach by the
Company of any covenant or condition contained in this Agreement or in any
Rights Certificate; nor shall it be responsible for any adjustment required
under the provisions of Section 11 or Section 13 hereof or responsible for the
manner, method or amount of any such adjustment or the ascertaining of the
existence of facts that would require any such adjustment (except with respect
to the exercise of Rights evidenced by Rights Certificates after actual notice
of any such adjustment); nor shall it by any act hereunder be deemed to make any
representation or warranty as to the authorization or reservation of any shares
of Common Stock to be issued pursuant to this Agreement or any Rights
Certificate or as to whether any shares of Common Stock will, when so issued, be
validly authorized and issued, fully paid and non-assessable.
(e) The Company agrees that it will perform, execute, acknowledge and
deliver or cause to be performed, executed, acknowledged and delivered all such
further and other acts, instruments and assurances as may reasonably be required
by the Rights Agent for the carrying out or performing by the Rights Agent of
the provisions of this Agreement.
<PAGE>
(f) The Rights Agent is hereby authorized and directed to accept
instructions with respect to the performance of its duties hereunder from the
Chairman of the Board, the President, any Vice President, the Secretary, any
Assistant Secretary, the Treasurer or any Assistant Treasurer of the Company,
and to apply to such officers for advice or instructions in connection with its
duties, and it shall not be liable to the Company or the holder of any Rights
Certificate or any shareholder of the Company for any action taken or suffered
to be taken by it in good faith in accordance with instructions of any such
officer.
(g) The Rights Agent and any stockholder, director, officer or employee
of the Rights Agent may buy, sell or deal in any of the Rights or other
securities of the Company or become pecuniarily interested in any transaction in
which the Company may be interested, or contract with or lend money to the
Company or otherwise act as fully and freely as though it were not Rights Agent
under this Agreement. Nothing herein shall preclude the Rights Agent from acting
in any other capacity for the Company or for any other legal entity.
(h) The Rights Agent may execute and exercise any of the rights or
powers hereby vested in it or perform any duty hereunder either itself or by or
through its attorneys or agents, and the Rights Agent shall not be answerable or
accountable for any act, default, neglect or misconduct of any such attorneys or
agents or for any loss to the Company resulting from any such act, default,
neglect or misconduct; provided, however, reasonable care was exercised in the
selection and continued employment thereof.
(i) No provision of this Agreement shall require the Rights Agent to
expend or risk its own funds or otherwise incur any financial liability in the
performance of any of its duties hereunder or in the exercise of its rights if
there shall be, in the sole judgment of the Rights Agent, reasonable grounds for
believing that repayment of such funds or adequate indemnification against such
risk or liability is not reasonably assured to it.
<PAGE>
(j) If, with respect to any Right Certificate surrendered to the Rights
Agent for exercise or transfer, the certificate attached to the form of
assignment or form of election to purchase, as the case may be, has either not
been completed or indicates an affirmative response to clause 1 and/or 2
thereof, the Rights Agent shall not take any further action with respect to such
requested exercise or transfer without first consulting with the Company.
Section 21. Change of Rights Agent. The Rights Agent or any successor
Rights Agent may resign and be discharged from its duties under this Agreement
upon thirty (30) days' notice in writing mailed to the Company, and to each
transfer agent of the Common Stock, by registered or certified mail, and to the
holders of the Rights Certificates by first-class mail. The Company may remove
the Rights Agent or any successor Rights Agent upon thirty (30) days' notice in
writing, mailed to the Rights Agent or successor Rights Agent, as the case may
be, and to each transfer agent of the Common Stock, by registered or certified
mail, and to the holders of the Rights Certificates by first-class mail. If the
Rights Agent shall resign or be removed or shall otherwise become incapable of
acting, the Company shall appoint a successor to the Rights Agent. If the
Company shall fail to make such appointment within a period of thirty (30) days
after giving notice of such removal or after it has been notified in writing of
such resignation or incapacity by the resigning or incapacitated Rights Agent or
by the holder of a Rights Certificate (who shall, with such notice, submit his
Rights Certificate for inspection by the Company), then any registered holder of
any Rights Certificate may apply to any court of competent jurisdiction for the
appointment of a new Rights Agent. Any successor Rights Agent, whether appointed
by the Company or by such a court, shall be a corporation organized and doing
business under the laws of the United States or of the State of Georgia or of
the State of New York (or of any other state of the United States so long as
such corporation is authorized to do business as a banking institution in either
the State of Georgia or the State of New York), in good standing, having a
principal office in either the State of Georgia or the State of New York, which
is authorized under such laws to exercise corporate trust powers and is subject
to supervision or examination by federal or state authority and which has at the
time of its appointment as Rights Agent a combined capital and surplus of at
least $50,000,000. After appointment, the successor Rights Agent shall be vested
with the same powers, rights, duties and responsibilities as if it had been
originally named as Rights Agent without further act or deed; but the
predecessor Rights Agent shall deliver and transfer to the successor Rights
Agent any property at the time held by it hereunder, and execute and deliver any
further assurance, conveyance, act or deed necessary for the purpose. Not later
than the effective date of any such appointment, the Company shall file notice
thereof in writing with the predecessor Rights Agent and each transfer agent of
the Common Stock and the Common Stock, and mail a notice thereof in writing to
the registered holders of the Rights Certificates. Failure to give any notice
provided for in this Section 21, however, or any defect therein, shall not
affect the legality or validity of the resignation or removal of the Rights
Agent or the appointment of the successor Rights Agent, as the case may be.
Section 22. Issuance of New Rights Certificates. Notwithstanding any of
the provisions of this Agreement or of the Rights to the contrary, the Company
may, at its option, issue new Rights Certificates evidencing Rights in such form
as may be approved by its Board of Directors to reflect any adjustment or change
in the Purchase Price and the number or kind or class of shares or other
securities or property purchasable under the Rights Certificates made in
accordance with the provisions of this Agreement. In addition, in connection
with the issuance or sale of shares of Common Stock following the Distribution
Date and prior to the redemption or expiration of the Rights, the Company (a)
shall, with respect to shares of Common Stock so issued or sold pursuant to the
exercise of stock options or under any employee plan or arrangement, or upon the
exercise, conversion or exchange of securities hereinafter issued by the
Company, and (b) may, in any other case, if deemed necessary or appropriate by
the Board of Directors of the Company, issue Rights Certificates representing
the appropriate number of Rights in connection with such issuance or sale;
provided, however, that (i) no such Rights Certificate shall be issued if, and
to the extent that, the Company shall be advised by counsel that such issuance
would create a significant risk of material adverse tax consequences to the
Company or the Person to whom such Rights Certificate would be issued, and (ii)
no such Rights Certificate shall be issued if, and to the extent that,
appropriate adjustments shall otherwise have been made in lieu of the issuance
thereof.
<PAGE>
Section 23. Redemption and Termination. (a) The Board of Directors of
the Company may, at its option, at any time prior to the earlier of (i) the
close of business on the tenth day (as such period may be extended pursuant to
the provisions of Section 27 hereof) following the Stock Acquisition Date, or
(ii) the Final Expiration Date, redeem all but not less than all of the then
outstanding Rights at a redemption price of $.01 per Right, as such amount may
be appropriately adjusted to reflect any stock split, stock dividend or similar
transaction occurring after the date hereof (such redemption price being
hereinafter referred to as the "Redemption Price"), such Redemption Price to be
payable in cash, shares of Common Stock (based on the "current market price," as
defined in Section 11(d) hereof, of the Common Stock at the time of redemption)
or such other form of consideration as may be deemed appropriate by the Board of
Directors of the Company; provided, however, that if following the occurrence of
a Stock Acquisition Date and following the expiration of the right of redemption
hereunder but prior to any Triggering Event, (i) a Person who is an Acquiring
Person shall have transferred or otherwise disposed of a number of shares of
Common Stock in one transaction or series of transactions, not directly or
indirectly involving the Company or any of its Subsidiaries, which did not
result in the occurrence of a Triggering Event such that such Person is
thereafter a Beneficial Owner of 5% or less of the outstanding shares of Common
Stock, and (ii) there are no other Persons, immediately following the occurrence
of the event described in clause (i), who are Acquiring Persons, then the right
of redemption shall be reinstated and thereafter be subject to the provisions of
this Section 23. Notwithstanding anything contained in this Agreement to the
contrary, the Rights shall not be exercisable after the first occurrence of a
Section 11(a)(ii) Event until such time as the Company's right of redemption
hereunder and under subsection (b) of this Section 23 has expired.
(b) During the period commencing at the close of business on the tenth
day following the Stock Acquisition Date and terminating on the earlier of (i)
the occurrence of a Triggering Event and (ii) the Final Expiration Date, the
Board of Directors of the Company may, at its option, redeem all but not less
than all of the then outstanding Rights at the Redemption Price (appropriately
adjusted to reflect any stock split, stock dividend or similar transaction
occurring after the date hereof), provided that such redemption is incidental to
a merger, consolidation or other business combination involving the Company or a
reorganization or restructuring of the Company which the Board of Directors
shall determine to be in the best interests of the Company and its stockholders.
<PAGE>
(c) Immediately upon the action of the Board of Directors of the
Company ordering the redemption of the Rights, evidence of which shall have been
filed with the Rights Agent and without any further action and without any
notice, the right to exercise the Rights will terminate each Right so held.
Promptly after the action of the Board of Directors ordering the redemption of
the Rights, the Company shall give notice of such redemption to the Rights Agent
and the holders of the then outstanding Rights by mailing such notice to all
such holders at each holder's last address as it appears upon the registry books
of the Rights Agent or, prior to the Distribution Date, on the registry books of
the Transfer Agent for the Common Stock. Any notice which is mailed in the
manner herein provided shall be deemed given, whether or not the holder receives
the notice. Each such notice of redemption will state the method by which the
payment of the Redemption Price will be made.
Section 24. Exchange. (a) The Board of Directors of the Company may, at
its option, at any time after the occurrence of a Triggering Event, exchange all
or part of the then outstanding and exercisable Rights (which shall not include
Rights that have become void pursuant to the provisions of Section 7(e) hereof)
for shares of Common Stock at an exchange ratio of one Common Share per Right,
appropriately adjusted to reflect any stock split, stock dividend or similar
transaction occurring after the date hereof (such exchange ratio being
hereinafter referred to as the "Exchange Ratio"). Notwithstanding the foregoing,
the Board of Directors shall not be empowered to effect such exchange at any
time after any Person (other than the Company, any Subsidiary of the Company,
any employee benefit plan of the Company or any such Subsidiary, or any entity
holding shares of Common Stock for or pursuant to the terms of any such plan),
together with all Affiliates and Associates of such Person, becomes the
Beneficial Owner of 50% or more of the shares of Common Stock then outstanding.
(b) Immediately upon the action of the Board of Directors of the
Company ordering the exchange of any Rights pursuant to paragraph (a) of this
Section 24 and without any further action and without any notice, the right to
exercise such Rights shall terminate and the only right thereafter of a holder
of such Rights shall be to receive that number of shares of Common Stock equal
to the number of such Rights held by such holder multiplied by the Exchange
Ratio. The Company shall promptly give public notice of any such exchange;
provided, however, that the failure to give, or any defect in, such notice shall
not affect the validity of such exchange. The Company promptly shall mail a
notice of any such exchange to all of the holders of such Rights at their last
addresses as they appear upon the registry books of the Rights Agent. Any notice
which is mailed in the manner herein provided shall be deemed given, whether or
not the holder receives the notice. Each such notice of exchange will state the
method by which the exchange of the shares of Common Stock for Rights will be
effected and, in the event of any partial exchange, the number of Rights which
will be exchanged. Any partial exchange shall be effected pro rata based on the
number of Rights (other than Rights which have become void pursuant to the
provisions of Section 7(e) hereof) held by each holder of Rights.
<PAGE>
(c) In the event that there shall not be sufficient shares of Common
Stock issued but not outstanding or authorized but unissued to permit any
exchange of Rights as contemplated in accordance with this Section 24, the
Company shall take all such action as may be necessary to authorize additional
shares of Common Stock for issuance upon exchange of the Rights. In the event
the Company shall, after good faith effort, be unable to take all such action as
may be necessary to authorize such additional shares of Common Stock, the
Company shall substitute, for each Common Share that would otherwise be issuable
upon exchange of a Right, a number of shares of Common Stock or fraction thereof
such that the current per share market price of one Common Share multiplied by
such number or fraction is equal to the current per share market price of one
Common Share as of the date of issuance of such shares of Common Stock or
fraction thereof.
(d) The Company shall not be required to issue fractions of shares of
Common Stock or to distribute certificates which evidence fractional shares of
Common Stock. In lieu of such fractional shares of Common Stock, the Company
shall pay to the registered holders of the Right Certificates with regard to
which such fractional shares of Common Stock would otherwise be issuable an
amount in cash equal to the same fraction of the current market value of a whole
Common Share. For the purposes of this paragraph (d), the current market value
of a whole Common Share shall be the closing price of a Common Share (as
determined pursuant to Section 11(d) hereof) for the Trading Day immediately
prior to the date of exchange pursuant to this Section 24.
Section 25. Notice of Certain Events. (a) In case the Company shall
propose, at any time after the Distribution Date, (i) to pay any dividend
payable in stock of any class to the holders of Common Stock or to make any
other distribution to the holders of Common Stock (other than a regular
quarterly cash dividend out of earnings or retained earnings of the Company), or
(ii) to offer to the holders of Common Stock rights or warrants to subscribe for
or to purchase any additional shares of Common Stock or shares of stock of any
class or any other securities, rights or options, or (iii) to effect any
reclassification of its Common Stock (other than a reclassification involving
only the subdivision of outstanding shares of Common Stock), or (iv) to effect
any consolidation or merger into or with any other Person (other than a
Subsidiary of the Company in a transaction which complies with Section 11(o)
hereof and has been approved by the Board of Directors), or to effect any sale
or other transfer (or to permit one or more of its Subsidiaries to effect any
sale or other transfer), in one transaction or a series of related transactions,
of 50% or more of the assets or earning power of the Company and its
Subsidiaries (taken as a whole) to any other Person or Persons (other than the
Company and/or any of its Subsidiaries in one or more transactions each of which
complies with Section 11(o) hereof and has been approved by the Board of
Directors), or (v) to effect the liquidation, dissolution or winding up of the
Company, then, in each such case, the Company shall give to each holder of a
Rights Certificate, to the extent feasible and in accordance with Section 26
hereof, a notice of such proposed action, which shall specify the record date
for the purposes of such stock dividend, distribution of rights or warrants, or
the date on which such reclassification, consolidation, merger, sale, transfer,
liquidation, dissolution, or winding up is to take place and the date of
participation therein by the holders of the shares of Common Stock, if any such
date is to be fixed, and such notice shall be so given in the case of any action
covered by clause (i) or (ii) above at least twenty (20) days prior to the
record date for determining holders of the shares of Common Stock for purposes
of such action, and in the case of any such other action, at least twenty (20)
days prior to the date of the taking of such proposed action or the date of
participation therein by the holders of the shares of Common Stock, whichever
shall be the earlier.
<PAGE>
(b) In case any Triggering Event shall occur, then, in any such case,
(i) the Company shall as soon as practicable thereafter give to each holder of a
Rights Certificate, to the extent feasible and in accordance with Section 26
hereof, a notice of the occurrence of such event, which shall specify the event
and the consequences of the event to holders of Rights under Section 11(a)(ii)
or Section 13 hereof as applicable, and (ii) all references in the preceding
paragraph to Common Stock shall be deemed thereafter to refer to Common Stock
and/or, if appropriate, other securities.
Section 26. Notices. Notices or demands authorized by this Agreement to
be given or made by the Rights Agent or by the holder of any Rights Certificate
to or on the Company shall be sufficiently given or made if sent by first-class
mail, postage prepaid, addressed (until another address is filed in writing with
the Rights Agent) as follows:
Matria Healthcare, Inc.
1850 Parkway Place
12th Floor
Marietta, Georgia 30067
Attention: Corporate Secretary
Subject to the provisions of Section 21, any notice or demand authorized by this
Agreement to be given or made by the Company or by the holder of any Rights
Certificate to or on the Rights Agent shall be sufficiently given or made if
sent by first-class mail, postage prepaid, addressed (until another address is
filed in writing with the Company) as follows:
SunTrust Bank, Atlanta
58 Edgewood Avenue
Atlanta, Georgia 30302
Attention: Manager, Corporate Trust Department
<PAGE>
Notices or demands authorized by this Agreement to be given or made by the
Company or the Rights Agent to the holder of any Rights Certificate (or, if
prior to the Distribution Date, to the holder of certificates representing
shares of Common Stock) shall be sufficiently given or made if sent by
first-class mail, postage prepaid, addressed to such holder at the address of
such holder as shown on the registry books of the Company.
Section 27. Supplements and Amendments. Subject to the penultimate
sentence of this Section 27 and with the consent of the Rights Agent, this
Agreement may be supplemented or amended at the times and for the purposes set
forth below. Prior to the Distribution Date and subject to the penultimate
sentence of this Section 27, the Company and the Rights Agent shall, if the
Company so directs, supplement or amend any provision of this Agreement without
the approval of any holders of certificates representing shares of Common Stock.
From and after the Distribution Date and subject to the penultimate sentence of
this Section 27, the Company and the Rights Agent shall, if the Company so
directs, supplement or amend this Agreement without the approval of any holders
of Rights Certificates in order (i) to cure any ambiguity, (ii) to correct or
supplement any provision contained herein which may be defective or inconsistent
with any other provisions herein, (iii) to shorten or lengthen any time period
hereunder, or (iv) to change or supplement the provisions hereunder in any
manner which the Company may deem necessary or desirable and which shall not
adversely affect the interests of the holders of Rights Certificates (other than
an Acquiring Person or an Affiliate or Associate of an Acquiring Person);
provided, this Agreement may not be supplemented or amended to lengthen,
pursuant to clause (iii) of this sentence, (A) subject to Section 31, a time
period relating to when the Rights may be redeemed at such time as the Rights
are not then redeemable, or (B) any other time period unless such lengthening is
for the purpose of protecting, enhancing or clarifying the rights of, and/or the
benefits to, the holders of the common equity of the Company, including the
holders of Rights. Upon the delivery of a certificate that is signed by an
officer of the Company and which states that the proposed supplement or
amendment is in compliance with the terms of this Section 27, the Rights Agent
shall execute such supplement or amendment. Notwithstanding anything contained
in this Agreement to the contrary, no supplement or amendment shall be made
which changes the Redemption Price, the Final Expiration Date, the Purchase
Price or the number of one one-hundredths of a share of Common Stock or other
securities or assets for which a Right is exercisable. Prior to the Distribution
Date, the interests of the holders of Rights shall be deemed coincident with the
interests of the holders of Common Stock.
<PAGE>
Section 28. Successors. All the covenants and provisions of this Agreement
by or for the benefit of the Company or the Rights Agent shall bind and inure to
the benefit of their respective successors and assigns hereunder.
Section 29. Determinations and Actions by the Board of Directors, etc.
For all purposes of this Agreement, any calculation of the number of shares of
Common Stock outstanding at any particular time, including for purposes of
determining the particular percentage of such outstanding shares of Common Stock
of which any Person is the Beneficial Owner, shall be made in accordance with
the last sentence of Rule 13d-3(d)(1)(i) of the General Rules and Regulations
under the Exchange Act. The Board of Directors of the Company shall have the
exclusive power and authority to administer this Agreement and to exercise all
rights and powers specifically granted to the Board or to the Company, or as may
be necessary or advisable in the administration of this Agreement, including,
without limitation, the right and power to (i) interpret the provisions of this
Agreement, and (ii) make all determinations deemed necessary or advisable for
the administration of this Agreement (including a determination to redeem or not
redeem the Rights or to amend the Agreement). All such actions, calculations,
interpretations and determinations (including, for purposes of clause (y) below,
all omissions with respect to the foregoing) which are done or made by the Board
in good faith, shall (x) be final, conclusive and binding on the Company, the
Rights Agent, the holders of the Rights and all other parties, and (y) not
subject the Board of Directors to any liability to the holders of the Rights.
Section 30. Benefits of this Agreement. Nothing in this Agreement shall
be construed to give to any Person other than the Company, the Rights Agent and
the registered holders of the Rights Certificates (and, prior to the
Distribution Date, registered holders of the Common Stock) any legal or
equitable right, remedy or claim under this Agreement; but this Agreement shall
be for the sole and exclusive benefit of the Company, the Rights Agent and the
registered holders of the Rights Certificates (and, prior to the Distribution
Date, registered holders of the Common Stock).
<PAGE>
Section 31. Severability. If any term, provision, covenant or
restriction of this Agreement is held by a court of competent jurisdiction or
other authority to be invalid, void or unenforceable, the remainder of the
terms, provisions, covenants and restrictions of this Agreement shall remain in
full force and effect and shall in no way be affected, impaired or invalidated;
provided, however, that notwithstanding anything in this Agreement to the
contrary, if any such term, provision, covenant or restriction is held by such
court or authority to be invalid, void or unenforceable and the Board of
Directors of the Company determines in its good faith judgment that severing the
invalid language from this Agreement would adversely affect the purpose or
effect of this Agreement, the right of redemption set forth in Section 23 hereof
shall be reinstated and shall not expire until the close of business on the
tenth day following the date of such determination by the Board of Directors.
Section 32. Governing Law. This Agreement, each Right and each Rights
Certificate issued hereunder shall be deemed to be a contract made under the
laws of the State of Georgia and for all purposes shall be governed by and
construed in accordance with the laws of such State applicable to contracts to
be made and to be performed entirely within such State.
Section 33. Counterparts. This Agreement may be executed in any number
of counterparts and each of such counterparts shall for all purposes be deemed
to be an original, and all such counterparts shall together constitute but one
and the same instrument.
Section 34. Descriptive Headings. Descriptive headings of the several
Sections of this Agreement are inserted for convenience only and shall not
control or affect the meaning or construction of any of the provisions hereof.
<PAGE>
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed and their respective corporate seals to be hereunto affixed and
attested, all as of the date and year first above written.
Attest: MATRIA HEALTHCARE, INC.
____________________________ By:_________________________
Name: Name:
Title: Title:
Attest: SUNTRUST BANK, ATLANTA
___________________________ By:________________________
Name: Name:
Title: Title:
<PAGE>
Exhibit A
[Form of Rights Certificate]
Certificate No. R- _____ Rights
NOT EXERCISABLE AFTER JANUARY 30, 2006 OR EARLIER IF REDEEMED OR EXCHANGED BY
THE COMPANY. THE RIGHTS ARE SUBJECT TO REDEMPTION, AT THE OPTION OF THE COMPANY,
AT $.01 PER RIGHT ON THE TERMS SET FORTH IN THE RIGHTS AGREEMENT. UNDER CERTAIN
CIRCUMSTANCES, RIGHTS BENEFICIALLY OWNED BY AN ACQUIRING PERSON (AS SUCH TERM IS
DEFINED IN THE RIGHTS AGREEMENT) AND ANY SUBSEQUENT HOLDER OF SUCH RIGHTS MAY
BECOME NULL AND VOID. [THE RIGHTS REPRESENTED BY THIS RIGHTS CERTIFICATE ARE OR
WERE BENEFICIALLY OWNED BY A PERSON WHO WAS OR BECAME AN ACQUIRING PERSON OR AN
AFFILIATE OR ASSOCIATE OF AN ACQUIRING PERSON (AS SUCH TERMS ARE DEFINED IN THE
RIGHTS AGREEMENT). ACCORDINGLY, THIS RIGHTS CERTIFICATE AND THE RIGHTS
REPRESENTED HEREBY MAY BECOME NULL AND VOID IN THE CIRCUMSTANCES SPECIFIED IN
SECTION 7(e) OF THE RIGHTS AGREEMENT.]1
Rights Certificate
MATRIA HEALTHCARE, INC.
This certifies that _______________________, or registered assigns, is the
registered owner of the number of Rights set forth above, each of which entitles
the owner thereof, subject to the terms, provisions and conditions of the
Amended and Restated Rights Agreement, dated as of April 27, 1999, as amended
from time to time (the "Rights Agreement"), between Matria Healthcare, Inc., a
Delaware corporation (the "Company"), and SunTrust Bank, Atlanta, a Georgia
banking corporation (the "Rights Agent"), to purchase from the Company at any
time prior to 5:00 PM (Eastern Standard Time) on January 30, 2006 (unless
earlier redeemed by the Company as provided in the Rights Agreement) at the
office or offices of the Rights Agent designated for such purpose, or its
successors as Rights Agent, one one-hundredth of a fully paid, non-assessable
share of Common Stock (the "Common Stock") of the Company, at a purchase price
of $.61 per one one-hundredth of a share (the "Purchase Price"), upon
presentation and surrender of this Rights Certificate with the Form of Election
to Purchase and related Certificate duly executed. The Purchase Price shall be
paid in cash. The number of Rights evidenced by this Rights Certificate (and the
number of shares which may be purchased upon exercise thereof) set forth above,
and the Purchase Price per share set forth above, are the number and Purchase
Price as of ___________________, 19__, based on the Common Stock as constituted
at such date.
<PAGE>
Upon the occurrence of a Section 11(a)(ii) Event (as such term is
defined in the Rights Agreement), if the Rights evidenced by this Rights
Certificate are beneficially owned by (i) an Acquiring Person or an Affiliate or
Associate of any such Acquiring Person (as such terms are defined in the Rights
Agreement), (ii) a transferee of any such Acquiring Person, Associate or
Affiliate, or (iii) under certain circumstances specified in the Rights
Agreement, a transferee of a person who, after such transfer, became an
Acquiring Person, or an Affiliate or Associate of an Acquiring Person, such
Rights shall become null and void and no holder hereof shall have any right with
respect to such Rights from and after the occurrence of such Section 11(a)(ii)
Event.
As provided in the Rights Agreement, the Purchase Price and the number
and kind of shares of Common Stock or other securities which may be purchased
upon the exercise of the Rights evidenced by this Rights Certificate are subject
to modification and adjustment upon the happening of certain events, including
Triggering Events (as such term is defined in the Rights Agreement).
This Rights Certificate is subject to all of the terms, provisions and
conditions of the Rights Agreement, which terms, provisions and conditions are
hereby incorporated herein by reference and made a part hereof and to which
Rights Agreement reference is hereby made for a full description of the rights,
limitations of rights, obligations, duties and immunities hereunder of the
Rights Agent, the Company and the holders of the Rights Certificates, which
limitations of rights include the temporary suspension of the exercisability of
such Rights under the specific circumstances set forth in the Rights Agreement.
Copies of the Rights Agreement are on file at the above-mentioned office of the
Rights Agent and are also available upon written request to the Rights Agent.
This Rights Certificate, with or without other Rights Certificates,
upon surrender at the principal office or offices of the Rights Agent designated
for such purpose, may be exchanged for another Rights Certificate or Rights
Certificates of like tenor and date evidencing Rights entitling the holder to
purchase a like aggregate number of one one-hundredths of a share of Common
Stock as the Rights evidenced by the Rights Certificate or Rights Certificates
surrendered shall have entitled such holder to purchase. If this Rights
Certificate shall be exercised in part, the holder shall be entitled to receive
upon surrender hereof another Rights Certificate or Rights Certificates for the
number of whole Rights not exercised.
<PAGE>
Subject to the provisions of the Rights Agreement, the Rights evidenced
by this Certificate may be redeemed by the Company at its option at a redemption
price of $.01 per Right at any time prior to the earlier of the close of
business on (i) the tenth day following the Stock Acquisition Date (as such time
period may be extended pursuant to the Rights Agreement), and (ii) the Final
Expiration Date. After the Expiration of the redemption period, the Company's
right of redemption may be reinstated if an Acquiring Person reduces his
beneficial ownership to 5% or less of the outstanding shares of Common Stock in
a transaction or series of transactions not involving the Company. In addition,
the Company may redeem the Rights after the above ten day period and prior to a
Triggering Event, incidental to a merger or other business combination involving
the Company or reorganization or restructuring of the Company which the Board of
Directors of the Company (as defined in the Rights Agreement) determines is in
the best interest of stockholders.
No fractional shares of Common Stock will be issued upon the exercise
of any Right or Rights evidenced hereby (other than fractions which are integral
multiples of one one-hundredth of a share of Common Stock, which may, at the
election of the Company, be evidenced by depositary receipts), but in lieu
thereof a cash payment will be made, as provided in the Rights Agreement.
No holder of this Rights Certificate shall be entitled to vote or
receive dividends or be deemed for any purpose the holder of shares of Common
Stock or of any other securities of the Company which may at any time be
issuable on the exercise hereof, nor shall anything contained in the Rights
Agreement or herein be construed to confer upon the holder hereof, as such, any
of the rights of a stockholder of the Company or any right to vote for the
election of directors or upon any matter submitted to stockholders at any
meeting thereof, or to give or withhold consent to any corporate action, or to
receive notice of meetings or other actions affecting stockholders (except as
provided in the Rights Agreement), or to receive dividends or subscription
rights, or otherwise, until the Right or Rights evidenced by this Rights
Certificate shall have been exercised as provided in the Rights Agreement.
This Rights Certificate shall not be valid or obligatory for any
purpose until it shall have been countersigned by the Rights Agent.
WITNESS the facsimile signature of the proper officer of the Company and
its corporate seal.
Dated as of _________________________, 19__
ATTEST: MATRIA HEALTHCARE, INC.
____________________________ By:_______________________
Secretary Title:____________________
Countersigned:
SunTrust Bank, Atlanta
By:_________________________
Authorized Signature
<PAGE>
[Form of Reverse Side of Rights Certificate]
FORM OF ASSIGNMENT
(To be executed by the registered holder if such holder desires to
transfer the Rights Certificate.)
FOR VALUE
RECEIVED___________________________________________________________________
hereby sells, assigns and transfers unto _____________________________________
- ------------------------------------------------------------------------------
(Please print name and address of transferee)
- ------------------------------------------------------------------------------
this Rights Certificate, together with all right, title and interest
therein, and does hereby irrevocably constitute and appoint _______________
Attorney, to transfer the within Rights Certificate on the books of the
within-named Company, with full power of
substitution.
Dated: ________________________,19____.
---------------------------
Signature
Signature Guaranteed:
<PAGE>
Certificate
The undersigned hereby certifies by checking the appropriate boxes
that:
(1) this Rights Certificate [ ] is [ ] is not being sold, assigned and
transferred by or on behalf of a Person who is or was an Acquiring Person or an
Affiliate or Associate of any such Acquiring Person (as such terms are defined
pursuant to the Rights Agreement);
(2) after due inquiry and to the best knowledge of the undersigned, it
[ ] did [ ] did not acquire the Rights evidenced by this Rights Certificate from
any Person who is, was or subsequently became an Affiliate or Associate of an
Acquiring Person.
Dated: ______________________, 19_____ ____________________________
Signature
Signature Guaranteed:
NOTICE
The signature to the foregoing Assignment and Certificate must
correspond to the name as written upon the face of this Rights Certificate in
every particular, without alteration or enlargement or any change whatsoever.
<PAGE>
FORM OF ELECTION TO PURCHASE
(To be executed if holder desires to
exercise Rights represented by the
Rights Certificate.)
To: MATRIA HEALTHCARE, INC:
The undersigned hereby irrevocably elects to exercise __________ Rights
represented by this Rights Certificate to purchase the shares of Common Stock
issuable upon the exercise of the Rights (or such other securities of the
Company or of any other person which may be issuable upon the exercise of the
Rights) and requests that certificates for such shares be issued in the name of
and delivered to:
Please insert social security
or other identifying number
- -----------------------------------------------------------------------------
(Please print name and address)
- -----------------------------------------------------------------------------
<PAGE>
If such number of Rights shall not be all the Rights evidenced by this
Rights Certificate, a new Rights Certificate for the balance of such Rights
shall be, registered in the name of and delivered to: Please insert social
security or other identifying number
- ------------------------------------------------------------------------------
(Please print name and address)
- ------------------------------------------------------------------------------
Dated:____________________, 19_____
---------------------------
Signature
Signature Guaranteed:
Certificate
The undersigned hereby certifies by checking the appropriate boxes
that:
(1) the Rights evidenced by this Rights Certificate [ ] are [ ] are not
being exercised by or on behalf of a Person who is or was an Acquiring Person or
an Affiliate or Associate of any such Acquiring Person (as such terms are
defined pursuant to the Rights Agreement);
(2) after due inquiry and to the best knowledge of the undersigned, it
[ ] did [ ] did not acquire the Rights evidenced by this Rights Certificate from
any Person who is, was or became an Acquiring Person or an Affiliate or
Associate of an Acquiring Person.
Dated:______________________, 19__ ____________________________________
Signature
Signature Guaranteed:
<PAGE>
NOTICE
The signature to the foregoing Election to Purchase and Certificate
must correspond to the name as written upon the face of this Rights Certificate
in every particular, without alteration or enlargement or any change whatsoever.
- --------
1 The portion of the legend in brackets shall be included only if applicable and
shall replace the preceding sentence.
